49 results on '"Koskinas, K"'
Search Results
2. Frequency, predictors and clinical outcomes of AMI patients with triple regression of coronary atherosclerosis: A sub-analysis of the PACMAN AMI trial
- Author
-
Biccire, F G, primary, Haner, J, additional, Ueki, Y, additional, Shibutani, H, additional, Otsuka, T, additional, Hofbauer, T M, additional, Van Jeuns, R J, additional, Spirk, D, additional, Daemen, J, additional, Iglesias, J, additional, Windecker, S, additional, Engstrom, T, additional, Lang, I, additional, Koskinas, K C, additional, and Raber, L, additional
- Published
- 2023
- Full Text
- View/download PDF
3. Effectiveness and safety of bempedoic acid in routine clinical practice: 1-year follow-up snapshot of the MILOS German cohort
- Author
-
Gouni-Berthold, I, primary, Koskinas, K, additional, Averna, M, additional, Stulnig, T, additional, Vanassche, T, additional, Blackburn, C, additional, Smolnik, R, additional, Soronen, J, additional, Wenz-Poschl, K, additional, Pinto, X, additional, and Parhofer, K, additional
- Published
- 2023
- Full Text
- View/download PDF
4. Effect of evolocumab on platelet function in patients with acute coronary syndromes. An analysis of the randomized, double-blind, placebo-controlled EVOPACS Trial
- Author
-
Koskinas, K C, primary, Mach, F, additional, Pedrazzini, G, additional, Mueller, C, additional, Cook, S, additional, Matter, C M, additional, Muller, O, additional, Haener, J, additional, Valgimigli, M, additional, Raeber, L, additional, Heg, D, additional, Windecker, S, additional, and Iglesias, J F, additional
- Published
- 2023
- Full Text
- View/download PDF
5. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
- Author
-
Lyon, A. R., Lopez-Fernandez, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., Cutter, D. J., de Azambuja, E., de Boer, R. A., Dent, S. F., Farmakis, D., Gevaert, S. A., Gorog, D. A., Herrmann, J., Lenihan, D., Moslehi, J., Moura, B., Salinger, S. S., Stephens, R., Suter, T. M., Szmit, S., Tamargo, J., Thavendiranathan, P., Tocchetti, C. G., van der Meer, P., van der Pal, H. J. H., Lancellotti, P., Thuny, F., Abdelhamid, M., Aboyans, V., Aleman, B., Alexandre, J., Barac, A., Borger, M. A., Casado-Arroyo, R., Cautela, J., Celutkiene, J., Cikes, M., Cohen-Solal, A., Dhiman, K., Ederhy, S., Edvardsen, T., Fauchier, L., Fradley, M., Grapsa, J., Halvorsen, S., Heuser, M., Humbert, M., Jaarsma, T., Kahan, T., Konradi, A., Koskinas, K. C., Kotecha, D., Ky, B., Landmesser, U., Lewis, B. S., Linhart, A., Lip, G. Y. H., Lochen, M. -L., Malaczynska-Rajpold, K., Metra, M., Mindham, R., Moonen, M., Neilan, T. G., Nielsen, J. C., Petronio, A. -S., Prescott, E., Rakisheva, A., Salem, J. -E., Savarese, G., Sitges, M., Ten Berg, J., Touyz, R. M., Tycinska, A., Wilhelm, M., Zamorano, J. L., Cardiovascular Centre (CVC), Restoring Organ Function by Means of Regenerative Medicine (REGENERATE), Group, ESC Scientific Document, Lyon, Alexander R, López-Fernández, Teresa, Couch, Liam S, Asteggiano, Riccardo, Aznar, Marianne C, Bergler-Klein, Jutta, Boriani, Giuseppe, Cardinale, Daniela, Cordoba, Raul, Cosyns, Bernard, Cutter, David J, de Azambuja, Evandro, de Boer, Rudolf A, Dent, Susan F, Farmakis, Dimitrio, Gevaert, Sofie A, Gorog, Diana A, Herrmann, Joerg, Lenihan, Daniel, Moslehi, Javid, Moura, Brenda, Salinger, Sonja S, Stephens, Richard, Suter, Thomas M, Szmit, Sebastian, Tamargo, Juan, Thavendiranathan, Paaladinesh, Tocchetti, Carlo G, van der Meer, Peter, van der Pal, Helena J H, Cardiology, Clinical sciences, and Cardio-vascular diseases
- Subjects
Cardiac magnetic resonance ,Cancer survivors ,Vascular endothelial growth factor inhibitors (VEGFi) ,Myocarditi ,Guideline ,Anthracycline ,Arrhythmias ,Medical Oncology ,T-CELL THERAPY ,Coronary artery disease ,Strain ,RECURRENT VENOUS THROMBOEMBOLISM ,Amyloid light-chain cardiac amyloidosis ,Androgen deprivation therapy ,Atrial fibrillation ,Biomarkers ,Cancer ,Carcinoid syndrome ,Cardiac tumour ,Cardio-oncology ,Cardiotoxicity ,Chemotherapy ,Echocardiography ,Fluoropyrimidine ,Guidelines ,Haematopoietic stem cell transplantation ,Heart failure ,Hormone therapy ,Hypertension ,Immunotherapy ,Ischaemic heart disease ,Myocarditis ,Pericardial disease ,Proteasome inhibitors ,Pulmonary hypertension ,QTc prolongation ,Radiotherapy ,Risk stratification ,Thrombosis ,Trastuzumab ,Valvular heart disease ,Venous thromboembolism ,Neoplasms ,Proteasome inhibitor ,Amyloid light-chain cardiac amyloidosi ,IMMUNE CHECKPOINT INHIBITORS ,Cardiotoxicity/diagnostic imaging ,Heart ,General Medicine ,Hematology ,MOLECULAR-WEIGHT HEPARIN ,BRAIN NATRIURETIC PEPTIDE ,oncology ,Cancer survivor ,Thrombosi ,CORONARY-ARTERY-DISEASE ,Cardiology and Cardiovascular Medicine ,TYROSINE KINASE INHIBITOR ,Arrhythmia ,Neoplasms/diagnostic imaging ,Antineoplastic Agents ,Humans ,Radiology, Nuclear Medicine and imaging ,EARLY BREAST-CANCER ,CARCINOID HEART-DISEASE ,Antineoplastic Agents/therapeutic use ,Biomarker ,AORTIC-VALVE-REPLACEMENT ,Radiation Oncology - Published
- 2022
6. Interrelation between baseline plaque characteristics and changes in coronary atherosclerosis with the PCSK9-inhibitor alirocumab: insights from the PACMAN-AMI randomized trial
- Author
-
Koskinas, K C, primary, Losdat, S, additional, Shibutani, H, additional, Ueki, Y, additional, Otsuka, T, additional, Haener, J, additional, Fahrni, G, additional, Iglesias, J F, additional, Spirk, D, additional, Van Geuns, R J, additional, Daemen, J, additional, Windecker, S, additional, Engstrom, T, additional, Lang, I, additional, and Raber, L, additional
- Published
- 2022
- Full Text
- View/download PDF
7. Impact of alirocumab added to high-intensity statin therapy on platelet function in AMI patients: a pre-specified substudy of the randomized, placebo-controlled PACMAN-AMI trial
- Author
-
Ueki, Y, primary, Haner, J, additional, Losdat, S, additional, Gargiulo, G, additional, Bar, S, additional, Otsuka, T, additional, Kavaliauskaite, R, additional, Mitter, V, additional, Temperli, F, additional, Shibutani, H, additional, Siontis, G, additional, Valgimigli, M, additional, Windecker, S, additional, Koskinas, K, additional, and Raber, L, additional
- Published
- 2022
- Full Text
- View/download PDF
8. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
- Author
-
Visseren, F, Mach, F, Smulders, Y, Carballo, D, Koskinas, K, Back, M, Benetos, A, Biffi, A, Boavida, J, Capodanno, D, Cosyns, B, Crawford, C, Davos, C, Desormais, I, Di Angelantonio, E, Duran, O, Halvorsen, S, Richard Hobbs, F, Hollander, M, Jankowska, E, Michal, M, Sacco, S, Sattar, N, Tokgozoglu, L, Tonstad, S, Tsioufis, K, van Dis, I, van Gelder, I, Wanner, C, Williams, B, De Backer, G, Regitz-Zagrosek, V, Aamodt, A, Abdelhamid, M, Aboyans, V, Albus, C, Asteggiano, R, Borger, M, Brotons, C, Celutkiene, J, Cifkova, R, Cikes, M, Cosentino, F, Dagres, N, De Backer, T, De Bacquer, D, Delgado, V, Ruijter, H, Dendale, P, Drexel, H, Falk, V, Fauchier, L, Ference, B, Ferrieres, J, Ferrini, M, Fisher, M, Fliser, D, Fras, Z, Gaita, D, Giampaoli, S, Gielen, S, Graham, I, Jennings, C, Jorgensen, T, Kautzky-Willer, A, Kavousi, M, Koenig, W, Konradi, A, Kotecha, D, Landmesser, U, Lettino, M, Lewis, B, Linhart, A, Lochen, M, Makrilakis, K, Mancia, G, Marques-Vidal, P, Mcevoy, J, Mcgreavy, P, Merkely, B, Neubeck, L, Nielsen, J, Perk, J, Petersen, S, Petronio, A, Piepoli, M, Pogosova, N, Prescott, E, Ray, K, Reiner, Z, Richter, D, Ryden, L, Shlyakhto, E, Sitges, M, Sousa-Uva, M, Sudano, I, Tiberi, M, Touyz, R, Ungar, A, Monique Verschuren, W, Wiklund, O, Wood, D, Zamorano, J, Visseren F., Mach F., Smulders Y. M., Carballo D., Koskinas K. C., Back M., Benetos A., Biffi A., Boavida J. -M., Capodanno D., Cosyns B., Crawford C. A., Davos C. H., Desormais I., Di Angelantonio E., Duran O. H. F., Halvorsen S., Richard Hobbs F. D., Hollander M., Jankowska E. A., Michal M., Sacco S., Sattar N., Tokgozoglu L., Tonstad S., Tsioufis K. P., van Dis I., van Gelder I. C., Wanner C., Williams B., De Backer G., Regitz-Zagrosek V., Aamodt A. H., Abdelhamid M., Aboyans V., Albus C., Asteggiano R., Borger M. A., Brotons C., Celutkiene J., Cifkova R., Cikes M., Cosentino F., Dagres N., De Backer T., De Bacquer D., Delgado V., Ruijter H. D., Dendale P., Drexel H., Falk V., Fauchier L., Ference B. A., Ferrieres J., Ferrini M., Fisher M., Fliser D., Fras Z., Gaita D., Giampaoli S., Gielen S., Graham I., Jennings C., Jorgensen T., Kautzky-Willer A., Kavousi M., Koenig W., Konradi A., Kotecha D., Landmesser U., Lettino M., Lewis B. S., Linhart A., Lochen M. -L., Makrilakis K., Mancia G., Marques-Vidal P., McEvoy J. W., McGreavy P., Merkely B., Neubeck L., Nielsen J. C., Perk J., Petersen S. E., Petronio A. S., Piepoli M., Pogosova N. G., Prescott E. I. B., Ray K. K., Reiner Z., Richter D. J., Ryden L., Shlyakhto E., Sitges M., Sousa-Uva M., Sudano I., Tiberi M., Touyz R. M., Ungar A., Monique Verschuren W. M., Wiklund O., Wood D., Zamorano J. L., Visseren, F, Mach, F, Smulders, Y, Carballo, D, Koskinas, K, Back, M, Benetos, A, Biffi, A, Boavida, J, Capodanno, D, Cosyns, B, Crawford, C, Davos, C, Desormais, I, Di Angelantonio, E, Duran, O, Halvorsen, S, Richard Hobbs, F, Hollander, M, Jankowska, E, Michal, M, Sacco, S, Sattar, N, Tokgozoglu, L, Tonstad, S, Tsioufis, K, van Dis, I, van Gelder, I, Wanner, C, Williams, B, De Backer, G, Regitz-Zagrosek, V, Aamodt, A, Abdelhamid, M, Aboyans, V, Albus, C, Asteggiano, R, Borger, M, Brotons, C, Celutkiene, J, Cifkova, R, Cikes, M, Cosentino, F, Dagres, N, De Backer, T, De Bacquer, D, Delgado, V, Ruijter, H, Dendale, P, Drexel, H, Falk, V, Fauchier, L, Ference, B, Ferrieres, J, Ferrini, M, Fisher, M, Fliser, D, Fras, Z, Gaita, D, Giampaoli, S, Gielen, S, Graham, I, Jennings, C, Jorgensen, T, Kautzky-Willer, A, Kavousi, M, Koenig, W, Konradi, A, Kotecha, D, Landmesser, U, Lettino, M, Lewis, B, Linhart, A, Lochen, M, Makrilakis, K, Mancia, G, Marques-Vidal, P, Mcevoy, J, Mcgreavy, P, Merkely, B, Neubeck, L, Nielsen, J, Perk, J, Petersen, S, Petronio, A, Piepoli, M, Pogosova, N, Prescott, E, Ray, K, Reiner, Z, Richter, D, Ryden, L, Shlyakhto, E, Sitges, M, Sousa-Uva, M, Sudano, I, Tiberi, M, Touyz, R, Ungar, A, Monique Verschuren, W, Wiklund, O, Wood, D, Zamorano, J, Visseren F., Mach F., Smulders Y. M., Carballo D., Koskinas K. C., Back M., Benetos A., Biffi A., Boavida J. -M., Capodanno D., Cosyns B., Crawford C. A., Davos C. H., Desormais I., Di Angelantonio E., Duran O. H. F., Halvorsen S., Richard Hobbs F. D., Hollander M., Jankowska E. A., Michal M., Sacco S., Sattar N., Tokgozoglu L., Tonstad S., Tsioufis K. P., van Dis I., van Gelder I. C., Wanner C., Williams B., De Backer G., Regitz-Zagrosek V., Aamodt A. H., Abdelhamid M., Aboyans V., Albus C., Asteggiano R., Borger M. A., Brotons C., Celutkiene J., Cifkova R., Cikes M., Cosentino F., Dagres N., De Backer T., De Bacquer D., Delgado V., Ruijter H. D., Dendale P., Drexel H., Falk V., Fauchier L., Ference B. A., Ferrieres J., Ferrini M., Fisher M., Fliser D., Fras Z., Gaita D., Giampaoli S., Gielen S., Graham I., Jennings C., Jorgensen T., Kautzky-Willer A., Kavousi M., Koenig W., Konradi A., Kotecha D., Landmesser U., Lettino M., Lewis B. S., Linhart A., Lochen M. -L., Makrilakis K., Mancia G., Marques-Vidal P., McEvoy J. W., McGreavy P., Merkely B., Neubeck L., Nielsen J. C., Perk J., Petersen S. E., Petronio A. S., Piepoli M., Pogosova N. G., Prescott E. I. B., Ray K. K., Reiner Z., Richter D. J., Ryden L., Shlyakhto E., Sitges M., Sousa-Uva M., Sudano I., Tiberi M., Touyz R. M., Ungar A., Monique Verschuren W. M., Wiklund O., Wood D., and Zamorano J. L.
- Published
- 2021
9. Revascularization in complex multivessel coronary artery disease after FREEDOM: Is there an indication for PCI and drug-eluting stents?
- Author
-
Koskinas, K. C. and Windecker, S.
- Published
- 2016
- Full Text
- View/download PDF
10. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
- Author
-
Visseren, F, Mach, F, Smulders, Y, Carballo, D, Koskinas, K, Bäck, M, Benetos, A, Biffi, A, Boavida, J, Capodanno, D, Cosyns, B, Crawford, C, Davos, C, Desormais, I, Di Angelantonio, E, Franco, O, Halvorsen, S, Hobbs, F, Hollander, M, Jankowska, E, Michal, M, Sacco, S, Sattar, N, Tokgozoglu, L, Tonstad, S, Tsioufis, K, van Dis, I, van Gelder, I, Wanner, C, Williams, B, De Backer, G, Regitz-Zagrosek, V, Aamodt, A, Abdelhamid, M, Aboyans, V, Albus, C, Asteggiano, R, Borger, M, Brotons, C, Celutkiene, J, Cifkova, R, Cikes, M, Cosentino, F, Dagres, N, De Backer, T, De Bacquer, D, Delgado, V, Den Ruijter, H, Dendale, P, Drexel, H, Falk, V, Fauchier, L, Ference, B, Ferrières, J, Ferrini, M, Fisher, M, Fliser, D, Fras, Z, Gaita, D, Giampaoli, S, Gielen, S, Graham, I, Jennings, C, Jorgensen, T, Kautzky-Willer, A, Kavousi, M, Koenig, W, Konradi, A, Kotecha, D, Landmesser, U, Lettino, M, Lewis, B, Linhart, A, Lochen, M, Makrilakis, K, Mancia, G, Marques-Vidal, P, Mcevoy, J, Mcgreavy, P, Merkely, B, Neubeck, L, Nielsen, J, Perk, J, Petersen, S, Petronio, A, Piepoli, M, Pogosova, N, Prescott, E, Ray, K, Reiner, Z, Richter, D, Rydén, L, Shlyakhto, E, Sitges, M, Sousa-Uva, M, Sudano, I, Tiberi, M, Touyz, R, Ungar, A, Verschuren, W, Wiklund, O, Wood, D, Zamorano, J, Visseren, FLJ, Smulders, YM, Koskinas, KC, Boavida, JM, Davos, CH, Franco, OH, Hobbs, FDR, Jankowska, EA, Tsioufis, KP, van Gelder, IC, Aamodt, AH, Borger, MA, Ference, BA, Lewis, BS, Lochen, ML, McEvoy, JW, McGreavy, P, Nielsen, JC, Petersen, SE, Petronio, AS, Pogosova, NG, Prescott, EIB, Ray, KK, Richter, DJ, Touyz, RM, Verschuren, WMM, Zamorano, JL, Visseren, F, Mach, F, Smulders, Y, Carballo, D, Koskinas, K, Bäck, M, Benetos, A, Biffi, A, Boavida, J, Capodanno, D, Cosyns, B, Crawford, C, Davos, C, Desormais, I, Di Angelantonio, E, Franco, O, Halvorsen, S, Hobbs, F, Hollander, M, Jankowska, E, Michal, M, Sacco, S, Sattar, N, Tokgozoglu, L, Tonstad, S, Tsioufis, K, van Dis, I, van Gelder, I, Wanner, C, Williams, B, De Backer, G, Regitz-Zagrosek, V, Aamodt, A, Abdelhamid, M, Aboyans, V, Albus, C, Asteggiano, R, Borger, M, Brotons, C, Celutkiene, J, Cifkova, R, Cikes, M, Cosentino, F, Dagres, N, De Backer, T, De Bacquer, D, Delgado, V, Den Ruijter, H, Dendale, P, Drexel, H, Falk, V, Fauchier, L, Ference, B, Ferrières, J, Ferrini, M, Fisher, M, Fliser, D, Fras, Z, Gaita, D, Giampaoli, S, Gielen, S, Graham, I, Jennings, C, Jorgensen, T, Kautzky-Willer, A, Kavousi, M, Koenig, W, Konradi, A, Kotecha, D, Landmesser, U, Lettino, M, Lewis, B, Linhart, A, Lochen, M, Makrilakis, K, Mancia, G, Marques-Vidal, P, Mcevoy, J, Mcgreavy, P, Merkely, B, Neubeck, L, Nielsen, J, Perk, J, Petersen, S, Petronio, A, Piepoli, M, Pogosova, N, Prescott, E, Ray, K, Reiner, Z, Richter, D, Rydén, L, Shlyakhto, E, Sitges, M, Sousa-Uva, M, Sudano, I, Tiberi, M, Touyz, R, Ungar, A, Verschuren, W, Wiklund, O, Wood, D, Zamorano, J, Visseren, FLJ, Smulders, YM, Koskinas, KC, Boavida, JM, Davos, CH, Franco, OH, Hobbs, FDR, Jankowska, EA, Tsioufis, KP, van Gelder, IC, Aamodt, AH, Borger, MA, Ference, BA, Lewis, BS, Lochen, ML, McEvoy, JW, McGreavy, P, Nielsen, JC, Petersen, SE, Petronio, AS, Pogosova, NG, Prescott, EIB, Ray, KK, Richter, DJ, Touyz, RM, Verschuren, WMM, and Zamorano, JL
- Published
- 2022
11. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
- Author
-
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Back, M., Benetos, A., Biffi, A., Boavida, J. -M., Capodanno, D., Cosyns, B., Crawford, C., Davos, C. H., Desormais, I., DI Angelantonio, E., Franco, O. H., Halvorsen, S., Hobbs, F. D. R., Hollander, M., Jankowska, E. A., Michal, M., Sacco, S., Sattar, N., Tokgozoglu, L., Tonstad, S., Tsioufis, K. P., Van DIs, I., Van Gelder, I. C., Wanner, C., Williams, B., De Backer, G., Regitz-Zagrosek, V., Aamodt, A. H., Abdelhamid, M., Aboyans, V., Albus, C., Asteggiano, R., Borger, M. A., Brotons, C., Ielutkiene, J., Cifkova, R., Cikes, M., Cosentino, F., Dagres, N., De Backer, T., De Bacquer, D., Delgado, V., Den Ruijter, H., Dendale, P., Drexel, H., Falk, V., Fauchier, L., Ference, B. A., Ferrieres, J., Ferrini, M., Fisher, M., Fliser, D., Fras, Z., Gaita, D., Giampaoli, S., Gielen, S., Graham, I., Jennings, C., Jorgensen, T., Kautzky-Willer, A., Kavousi, M., Koenig, W., Konradi, A., Kotecha, D., Landmesser, U., Lettino, M., Lewis, B. S., Linhart, A., Lochen, M. -L., Makrilakis, K., Mancia, G., Marques-Vidal, P., Mcevoy, J. W., Mcgreavy, P., Merkely, B., Neubeck, L., Nielsen, J. C., Perk, J., Petersen, S. E., Petronio, A. S., Piepoli, M., Pogosova, N. G., Prescott, E. I. B., Ray, K. K., Reiner, Z., Richter, D. J., Ryden, L., Shlyakhto, E., Sitges, M., Sousa-Uva, M., Sudano, I., Tiberi, M., Touyz, R. M., Ungar, A., Verschuren, W. M. M., Wiklund, O., Wood, D., Zamorano, J. L., Crawford, C. A., Franco Duran, O. H., Richard Hobbs, F. D., Dis, I. V., Group, ESC Scientific Document, Clinical sciences, Cardio-vascular diseases, and Cardiology
- Subjects
medicine.medical_specialty ,Epidemiology ,Population ,air pollution ,population ,Guidelines ,blood pressure ,climate change ,diabetes ,healthy lifestyle ,lifetime benefit ,lifetime risk ,lipids ,nutrition ,personalized ,prevention ,psychosocial factors ,risk estimation ,risk management ,shared decision-making ,smoking ,stepwise approach ,Risk Assessment ,Humans ,Primary Prevention ,Risk Factors ,Cardiovascular Diseases ,Diabetes mellitus ,medicine ,Intensive care medicine ,education ,610 Medicine & health ,Risk management ,education.field_of_study ,business.industry ,medicine.disease ,Clinical Practice ,Blood pressure ,guidelines ,Heart failure ,Lifetime risk ,Disease prevention ,Cardiology and Cardiovascular Medicine ,business ,Stepwise approach ,360 Social problems & social services - Abstract
These are the clinical practice guidelines from the European Society of Cardiology on cardiovascular disease prevention in clinical practice, from 2021.
- Published
- 2022
12. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy
- Author
-
Glikson, M., Nielsen, J. C., Kronborg, M. B., Michowitz, Y., Auricchio, A., Barbash, I. M., Barrabes, J. A., Boriani, G., Braunschweig, F., Brignole, M., Burri, H., Coats, A. J. S., Deharo, J. -C., Delgado, V., Diller, G. -P., Israel, C. W., Keren, A., Knops, R. E., Kotecha, D., Leclercq, C., Merkely, B., Starck, C., Thylen, I., Tolosana, J. M., Leyva, F., Linde, C., Abdelhamid, M., Aboyans, V., Arbelo, E., Asteggiano, R., Baron-Esquivias, G., Bauersachs, J., Biffi, M., Birgersdotter-Green, U., Bongiorni, M. G., Borger, M. A., Celutkiene, J., Cikes, M., Daubert, J. -C., Drossart, I., Ellenbogen, K., Elliott, P. M., Fabritz, L., Falk, V., Fauchier, L., Fernandez-Aviles, F., Foldager, D., Gadler, F., De Vinuesa, P. G. G., Gorenek, B., Guerra, J. M., Hermann Haugaa, K., Hendriks, J., Kahan, T., Katus, H. A., Konradi, A., Koskinas, K. C., Law, H., Lewis, B. S., Linker, N. J., Lochen, M. -L., Lumens, J., Mascherbauer, J., Mullens, W., Nagy, K. V., Prescott, E., Raatikainen, P., Rakisheva, A., Reichlin, T., Ricci, R. P., Shlyakhto, E., Sitges, M., Sousa-Uva, M., Sutton, R., Suwalski, P., Svendsen, J. H., Touyz, R. M., Van Gelder, I. C., Vernooy, K., Waltenberger, J., Whinnett, Z., Witte, K. K., Qoriany, A., Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), and Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)
- Subjects
Pacemaker, Artificial ,Cardiac pacing ,medicine.medical_treatment ,[SDV]Life Sciences [q-bio] ,Vascular damage Radboud Institute for Health Sciences [Radboudumc 16] ,cardiac resynchronization therapy ,heart failure ,temporary pacing ,law.invention ,law ,atrial fibrillation ,610 Medicine & health ,ComputingMilieux_MISCELLANEOUS ,biology ,Cardiac Pacing, Artificial ,Syncope (genus) ,Atrial fibrillation ,syncope ,Cardiology ,cardiovascular system ,medicine.symptom ,guidelines ,cardiac pacing ,pacemaker ,conduction system pacing ,pacing indications ,alternate site pacing ,complications ,pacing in TAVI ,bradycardia ,Cardiology and Cardiovascular Medicine ,Bradycardia ,medicine.medical_specialty ,Cardiac resynchronization therapy ,Guidelines ,Physiology (medical) ,Internal medicine ,medicine ,Humans ,Task force ,business.industry ,Stroke Volume ,1103 Clinical Sciences ,medicine.disease ,biology.organism_classification ,Heart Rhythm ,Cardiovascular System & Hematology ,Heart failure ,Artificial cardiac pacemaker ,business ,Atrioventricular block - Abstract
These are the clinical practice guidelines of the European Society of Cardiology on cardiac pacing and cardiac resynchronization therapy, from 2021.
- Published
- 2022
- Full Text
- View/download PDF
13. Frequency and prognostic impact of periprocedural myocardial infarction determined by various MI definitions in patients with chronic coronary syndromes undergoing percutaneous coronary intervention
- Author
-
Ueki, Y., Otsuka, T., Bar, S., Koskinas, K., Losdat, S., Heg, D., Zanchin, T., Siontis, G., Praz, F., Haner, J., Susuri, N., Stortecky, S., Thomas Pilgrim, Windecker, S., and Raber, L.
- Subjects
Cardiology and Cardiovascular Medicine - Abstract
Background Several definitions of peri-procedural myocardial infarction (MI) requiring different biomarker thresholds with or without ancillary criteria for myocardial ischemia are currently recommended without being fully validated in real-world patients with chronic coronary syndrome (CCS) undergoing percutaneous coronary intervention (PCI). Objectives We aimed to evaluate the prevalence and prognostic value of high-sensitivity cardiac troponin-based peri-procedural MI according to contemporary MI definitions using a large real-world PCI cohort. Methods In CCS patients undergoing elective PCI enrolled to the Bern PCI registry (NCT02241291) between 2010 and 2018, peri-procedural myocardial injury and infarction were assessed according to the 4th and 3rd universal definition of MI (UDMI), academic research consortium (ARC)-2, and Society for Cardiovascular Angiography and Interventions (SCAI) criteria. The primary endpoint was cardiac death at 1 year. Results Among 4404 CCS patients, peri-procedural MI defined by the 4th UDMI, 3rd UDMI, ARC-2, and SCAI were observed in 14.9%, 18.0%, 2.0%, and 2.0% of patients, respectively. Cardiac mortality at 1 year in patients with peri-procedural MI defined by 4th UDMI, 3rd UDMI, ARC-2, and SCAI were 3.0%, 2.9%, 5.8%, and 10.0%, respectively. After multivariate adjustments, peri-procedural MI defined by the ARC-2 and SCAI were independently associated with cardiac death at 1 year, while those defined by the 4th and 3rd UDMI were not. Conclusion Among CCS patients undergoing PCI, periprocedural MIs defined by theARC-2 and SCAI occurred 7 to 9 times less frequently as compared with the 4th and 3rd UDMI, and were the only definitions significantly associated with cardiac mortality. Funding Acknowledgement Type of funding sources: None. Cardiac death at 1 year
- Published
- 2021
14. Clinical use of intracoronary imaging. Part 1: guidance and optimization of coronary interventions. An expert consensus document of the European Association of Percutaneous Cardiovascular Interventions
- Author
-
Raber, L., Mintz, G. S., Koskinas, K. C., Johnson, T. W., Holm, N. R., Onuma, Y., Radu, M. D., Joner, M., Yu, B., Jia, H., Meneveau, N., De La Torre Hernandez, J. M., Escaned, J., Hill, J., Prati, F., Colombo, A., Di Mario, C., Regar, E., Capodanno, D., Wijns, W., Byrne, R. A., Guagliumi, G., Alfonso, F., Bhindi, R., Ali, Z., Carter, R., University of Zurich, Guagliumi, Giulio, and Cardiology
- Subjects
Percutaneous ,medicine.medical_treatment ,Psychological intervention ,Coronary Artery Disease ,030204 cardiovascular system & hematology ,Coronary Angiography ,Graft Occlusion ,Coronary artery disease ,Postoperative Complications ,0302 clinical medicine ,Restenosis ,Intravascular ultrasound ,Percutaneous coronary intervention (PCI) ,030212 general & internal medicine ,Tomography ,Ultrasonography ,Interventional ,medicine.diagnostic_test ,Graft Occlusion, Vascular ,Prosthesis Failure ,Treatment Outcome ,surgical procedures, operative ,Stents ,Cardiology and Cardiovascular Medicine ,Tomography, Optical Coherence ,medicine.medical_specialty ,Consensus ,610 Medicine & health ,2705 Cardiology and Cardiovascular Medicine ,03 medical and health sciences ,Percutaneous Coronary Intervention ,Vascular ,Medical imaging ,medicine ,Humans ,Medical physics ,cardiovascular diseases ,Ultrasonography, Interventional ,Optical coherence tomography ,business.industry ,Percutaneous coronary intervention ,Stent ,Intracoronary imaging ,equipment and supplies ,medicine.disease ,10020 Clinic for Cardiac Surgery ,Optical Coherence ,Conventional PCI ,business - Abstract
This Consensus Document is the first of two reports summarizing the views of an expert panel organized by the European Association of Percutaneous Cardiovascular Interventions (EAPCI) on the clinical use of intracoronary imaging including intravascular ultrasound (IVUS) and optical coherence tomography (OCT). The first document appraises the role of intracoronary imaging to guide percutaneous coronary interventions (PCIs) in clinical practice. Current evidence regarding the impact of intracoronary imaging guidance on cardiovascular outcomes is summarized, and patients or lesions most likely to derive clinical benefit from an imaging-guided intervention are identified. The relevance of the use of IVUS or OCT prior to PCI for optimizing stent sizing (stent length and diameter) and planning the procedural strategy is discussed. Regarding post-implantation imaging, the consensus group recommends key parameters that characterize an optimal PCI result and provides cut-offs to guide corrective measures and optimize the stenting result. Moreover, routine performance of intracoronary imaging in patients with stent failure (restenosis or stent thrombosis) is recommended. Finally, strengths and limitations of IVUS and OCT for guiding PCI and assessing stent failures and areas that warrant further research are critically discussed.
- Published
- 2018
15. Assessing the cardiology community position on transradial intervention and the use of bivalirudin in patients with acute coronary syndrome undergoing invasive management: results of an EAPCI survey
- Author
-
Adamo, Marianna, Byrne, Robert A., Baumbach, Andreas, Haude, Michael, Windecker, Stephan, Valgimigli, Marco, Aaroe, J., Abdeltawab, A. A., Accardi, R., Addad, F., Agostoni, P., Alajab, A., Alcázar, E., Alhabil, B., Altug Cakmak, H., Amico, F., Amoroso, G., Anderson, R., Andò, G., Andreou, A. Y., Antoniadis, D., Aquilina, M., Aramberry, L., Auer, J., Auffret, V., Ausiello, A., Austin, D., Avram, A., Ayman, E., Babunashvili, V., Bagur, R., Bakotic, Z., Balducelli, M., Ballesteros, S. M., Baptista, S., Baranauskas, A., Barbeau, G., Bax, M., Benchimol, C., Berroth, R., Biasco, L., Bilal, A., Binias, K., Blanco Mata, R., Boccuzzi, G., Bolognese, L., Boskovic, S., Bourboulis, N., Briguori, C., Bunc, M., Buysschaert, I., Calabro’, P., Campo, G., Candiello, A., Caprotta, U. F., Cardenas, M., Carrilho-Ferreira, P., Carrizo, S., Caruso, M., Cassar, A., Cernigliaro, C., Chacko, G., Chamie, D., Clapp, B., Coceani, M., Colangelo, S., Colombo, A., Comeglio, M., Connaughton, M., Conway, D., Cortese, B., Cosgrave, J., Costa, F., Couvoussis, E., Crimi, G., Crook, R., Cruz-Alvarado, J. E., Curello, S., D’Ascenzo, F., D’Urbano, M., Dana, A., De Backer, O., De Carlo, M., De Cesare, N., De Iaco, G., De La Torre, H. J. M., De Oliveira Netoj, B., Devlin, G. P., Di Lorenzo, E., Díaz, A., Dina, C., Dorsel, T. H., Eberli, F. R., Echeverría, R., Eftychiou, C., Elguindy, A., Ercilla, J., Ernst, A., Esposito, G., Ettori, F., Eufracino, Null, Ezquerra Aguilera, W., Falcone, C., Falu, R. M., Feres, F., Ferlini, M., Fernández, G., Fernández-Rodríguez, D., Fileti, L., Fischetti, D., Florescu, N., Formigli, D., Fouladvand, F., Franco, N., Fresco, C., Frigoli, E., Furmaniuk, J., Gabaldo, K., Galli, M., Galli, S., Garbo, R., Garducci, S., Garg, S., Gavrielatos, G., Gensch, J., Giacchi, G., Giunio, L., Giustino, G., Goldberg, L., Goldsmit, R., Gommeaux, A., González Godínez, H., Gosselin, G., Govorov, A., Grimfjard, P., Gross, E., Grosz, C., Guagliumi, G., Hadad, W., Hadadi, L., Hansen, P. R., Harb, S., Hatrick, R., Hayrapetyan, H. G., Hernández-Enríquez, M., Ho Heo, J., Horvath, I. G., Huan Loh, P., Ibrahim, A. M., Ierna, S., Ilic, I., Imperadore, F., Ionescu-Silva, E., Jacksch, R., James, S., Janiak, B., Jensen, S. E., Jeroen, S., Jugessur, R. K., Kala, P., Kambis, M., Kanakakis, J., Karamasis, G., Karchevsky, D., Karpovskiy, A., Kayaert, P., Kedev, S., Kemala, E., Ketteler, T., Khan, S. Q., Kharlamov, A., Kiernan, T., Kiviniem, T., Koltowski, L., Koskinas, K. C., Kouloumpinis, A., Kraaijeveld, A. O., Krizanic, F., Krötz, B., Kuczmik, W., Kukreja, N., Kuksa, D., Yav, K., Kyriakos, D., Labrunie, A., Laine, M., Lapin, O., Larosa, C., Latib, A., Lattuca, B., Lauer, B., Lefèvre, T., Legrand, V., Lehto, P., Leiva-Pons, J. L., Leone, A. M., Lev, G., Lim, R., Limbruno, U., Linares Vicente, J. A., Lindsay, S., Linnartz, C., Liso, A., Lluberas, R., Locuratolo, N., Lokshyn, S., Lunde, K., Lupi, A., Magnavacchi, P., Maia, F., Mainar, V., Mancone, M., Manolios, M. G., Mansour, S., Mariano, E., Marques, K., Martins, H., Mckenzie, D., Meco, S., Meemook, K., Mehmed, K., Melikyan, A., Mellwig, K. P., Mendiz, O. A., Merkulov, E., Mesquita, H. G., Mezzapelle, G., Miloradovic, V., Mohamed, S., Mohammed, B., Mohammed, F., Mohammed, K., Mohanad, A., Morawiec, B., More, R., Moreno-Martínez, F. L., Mrevlje, B., Muhammad, F., Näveri, H., Nazzaro, M. S., Neary, P., Negus, B. H., Nelson Durval, F. G., Nick, H., Nilva, E., Oldroyd, K. G., Olivares Asencio, C., Omerovic, E., Ortiz, M. A., Ota, H., Otasevic, P., Otieno, H. A., Paizis, I., Papp, E., Pasquetto, G., Patsourakos, N. G., Peels, J., Pelliccia, F., Pennacchi, M., Penzo, C., Perez, P., Perkan, A., Petrou, E., Phipathananunth, W., Pierri, A., Pinheiro, L. F., Pipa, J. L., Piva, T., Polad, J., Porto, I., Poveda, J., Predescu, L., Prog, R., Puri, R., Raco, D. L., Ramazan, O., Ramazzotti, V., Rao, S. V., Raungaard, B., Reczuch, K., Rekik, S., Rhouati, A., Rigattieri, S., Rodríguez-Olivares, R., Roik, M., Romagnoli, E., Román, A. J., Routledge, H., Rubartelli, P., Rubboli, A., Ruiz-García, J., Russo, F., Ruzsa, Z., Ryding, A., Saad, Aly, Sabate, M., Sabouret, P., Sadowski, M., Saia, F., Sanchez Perez, I., Santoro, G. M., Sarenac, D., Saririan, M., Sarma, J., Schuetz, T., Sciahbasi, A., Sebastian, M., Sebik, R., Sesana, M., Hur, Seung-Ho, Sganzerla, P., Shalva, R., Sharma, S., Sheiban, I., Shein, K. K., Shiekh, I. A., Sinha, M., Slhessarenko, J., Smith, D., Smyth, D. W., Sönmez, K., Sood, N., Sourgounis, A., Srdanovic, I., Stables, R. H., Stefanini, G. G., Stewart, J., Stoyanov, N., Suliman, A. A., Suryadevara, R., Suwannasom, P., Tange Veien, K., Tauchert, S., Tebet, M., Testa, L., Thury, A., Tilsted, H. H., Tiroch, K., Torres, A., Tosi, P., Traboulsi, M., Trani, C., Tresoldi, S., Tsigkas, G., Tueller, D., Turri, M., Udovichenko, A. E., Uretsky, B., Van Der Harst, P., Van Houwelingen, K. G., Vandoni, P., Vandormael, M., Varbella, F., Venkitachalam, C. G., Vercellino, M., Vidal-Perez, R., Vigna, C., Vignali, L., Vogt, F., Voudris, V., Vranckx, P., Vrolix, M., Vydt, T., Webster, M., Wijns, W., Woody, W., Wykrzykowska, J., Yazdani, S., Yildiz, A., Yurlevich, D., Zauith, R., Zekanovic, D., Zhao, M., Zimarino, M., Zingarelli, A., Abdelsamad, A. Y., Abo Shaera, E. S., Afshar, M. S., Agatiello, C., Aguiar, P., Ahmad, A. M., Akin, I., Alameda, M., Alegría-Barrero, E., Alejos, R., Alkhashab, K., Alkutshan, R. S. A., Almorraweh, A., Altnji, I., Alvarez Iorio, C., Anchidin, O., Angel, J., Antonopoulos, A., Apshilava, G., Arana, C., Ashikaga, T., Assomull, R., Atef, S. Z., Azmus, A. D., Azzalini, L., Azzouz, A., Baglioni, P., Bampas, G., Basil, M. P., Baumbach, A., Besh, D., Bhushan Sharm, A., Bien Hsien, H., Bihui, L., Bing-Chen, L., Biryukov, S., Blatt, A., Bocchi, E., Boghdady, A., Bonarjee, V. V. S., Bosnjak, I., Bravo Baptista, S., Brinckman, S. L., Buchter, B., Burzotta, F., Cacucci, M., Cagliyan, C. E., Calabrò, P., Cernetti, C., Chávez Mizraym, R., Choo, W. S., Choudhury, R., Cicco, N., Cisneros Clavijo, P., Çitaku, H., Collet, J. P., Consuegra-Sánchez, L., Conte, M., Corral, J. M., Damonte, A., Dangoisse, V., Dastani, M., Della Rosa, F., Deora, S., Devadathan, S., Dharma, S., Di Giorgio, A., Diez, J. L., Dinesha, B., Duplančić, D., El Behwashi, M. F., Elghawaby, H., Elshahawy, O., Eskola, M. J., Etman, A., Eun Gyu, L., Fabiano, L., Facta, A., Fan, Y., Fang-Yang, H., Farag, E., Fathi, Y., Fazeli, N., Federico, P., Fereidoun, M. Z., Fernandez-Nofrerias, E., Flensted Lassen, J., Flessas, D., Fouad, H., Franco-Pelaez, J. A., Fu, Q., Furtado, R., Gadepalli, R., Gallino, R., Gasparetto, V., Gentiletti, A., Gholoobi, A., Ghosh, A. K., Gkizas, S., Golchha, S. K., Goncharov, A., Gössl, M., Götberg, M., Greco, F., Grundeken, M. J., Gupta, D., Gupta, S., Guray, U., Hahalis, G., Hakim Vista, J., Hamid, M. A., Hammoudeh, A., Hasan, A. R. I., Hatsumura, F. E., Heintzen, M. P., Helal, T., Hetherington, S., Hewarathna, U. I., Hioki, H., Hissein, F., Ho-Ping, Y., Homs, S., Huber, K., Ibarra, F. M., Ielasi, A., Ipek, E., Jambunathan, R., Jamshidi, P., Jarrad, I., Javier, W., Jensen, J., Jimenez-Quevedo, P., Kalpak, O., Kan, J., Kanaan, T., Kao, D. H. M., Karamfiloff, K., Karegren, A., Karjalainen, P. P., Kasabov, R., Katsimagklis, G. D., Kaul, U., Khan, A., Kiemeneij, E., Kiviniemi, T., Kleiban, A., Komiyama, N., Konteva, M., Koshy, G., Krepsky, A. M., Kuljit, S., Kulkarni, P., Kumar, V., Kuznetsov, I., Lai, G., Lateef, M. A., Lawand, S., Le Hong, T., Lettieri, C., Levy, G., Lindvall, P., Maitra, A., Makowski, M., Mamas, M. A., Mandal, S. C., Mangalanandan, P., Marin, R., Mashhadi, M., Matsukage, T., Meier, B., Milosavljevic, B., Miro, S. S., Mitov, A., Moeriel, M., Moguel, R., Mohanty, A., Montalescot, G., Mörsdorf, W., Moscato, F., Muniz, A., Muraglia, S., Myć, J., Nada, A., Nair, P., Namazi, M. H., Naraghipour, F., Nguyen, Q. N., Nicosia, A., Nikas, D., Ober, M., Ocaranza-Sánchez, R., Olivecrona, G., Pahlajani, D., Pandey, B. P., Parma, A., Parma, R., Patsilinakos, S. P., Pattam, J., Peddi, S., Perez, P. R., Peruga, J. Z., Pescoller, F., Petrov, I., Piatti, L., Pico-Aracil, F., Pina, J., Piroth, Z., Popa, V., Pourbehi, M. R., Pradhan, A. K., Prida, X. E., Purohit, B. V., Pyun, W. B., Quang Hung, D., Rada, I., Rafizadeh, O., Rahman, M. A., Rai, L., Ramsewak, A., Ravindran, R., Rodriguez De Leiras, O. S., Rodríguez Esteban, M., Roque Figueira, H., Saket, A., Sakhov, O., Saktheeswaran, M. K., Salachas, A., Sallam, A., Sampaolesi, A., Samy, A., Sanchis, J., Santaera, O., Santarelli, A., Santharaj, W. S., Sarango, B., Satheesh, S., Schmitz, T., Schühlen, H., Seewoosagur, R., Segev, A., Seisembekov, V., Semitko, S., Sengottuvelu, G., Sepulveda Varela, P., Sethi, A., Sharma, A., Sharma, R. K., Shi, Hy., Şimşek, M. A., Siqueira, B., Skalidis, E., Slawin, J., Sorokhtey, L., Spaulding, C., Srinivas, B., Srinivasan, M., Stakos, D., Stefanini, G., Stojkovic, S., Tacoy, G., Tawade, M., Tiecco, F., Tondi, S., Torresani, E. M., Tousek, P., Tran, T., Trantalis, G., Triantafyllou, K., Trivedi, R., Trivisonno, A., Tsui, K. L., Türkoğlu, C., Tzung-Dau, W., Ueno, H., Urban, U., Uretsky, B. F., Uscumlic, A., Venugopal, V., Verney, R., Vilar, J. V., Villacorta, V. G., Vishwanath, R., Vlachojannis, G. J., Vlachojannis, M., Vlad, V., Von Birgelen, C., Vukcevic, V., Wahab, A., Waksman, R., Wei-Wen, L., Weisz, G., Whittaker, A., Yadav, A., Yokoi, Y., Zacharoulis, A., Zahran, M., Zamani, J., Ziakas, A., Zimmermann, J. P., Adamo, M., Byrne, R. A., Baumbach, A., Haude, M., Windecker, S., Valgimigli, M., Aaroe, J., Abdeltawab, A. A., Accardi, R., Addad, F., Agostoni, P., Alajab, A., Alcazar, E., Alhabil, B., Altug Cakmak, H., Amico, F., Amoroso, G., Anderson, R., Ando, G., Andreou, A. Y., Antoniadis, D., Aquilina, M., Aramberry, L., Auer, J., Auffret, V., Ausiello, A., Austin, D., Avram, A., Ayman, E., Babunashvili, V., Bagur, R., Bakotic, Z., Balducelli, M., Ballesteros, S. M., Baptista, S., Baranauskas, A., Barbeau, G., Bax, M., Benchimol, C., Berroth, R., Biasco, L., Bilal, A., Binias, K., Blanco Mata, R., Boccuzzi, G., Bolognese, L., Boskovic, S., Bourboulis, N., Briguori, C., Bunc, M., Buysschaert, I., Calabro', P., Campo, G., Candiello, A., Caprotta, U. F., Cardenas, M., Carrilho-Ferreira, P., Carrizo, S., Caruso, M., Cassar, A., Cernigliaro, C., Chacko, G., Chamie, D., Clapp, B., Coceani, M., Colangelo, S., Colombo, A., Comeglio, M., Connaughton, M., Conway, D., Cortese, B., Cosgrave, J., Costa, F., Couvoussis, E., Crimi, G., Crook, R., Cruz-Alvarado, J. E., Curello, S., D'Ascenzo, F., D'Urbano, M., Dana, A., De Backer, O., De Carlo, M., De Cesare, N., De Iaco, G., De La Torre, H. J. M., De Oliveira Netoj, B., Devlin, G. P., Di Lorenzo, E., Diaz, A., Dina, C., Dorsel, T. H., Eberli, F. R., Echeverria, R., Eftychiou, C., Elguindy, A., Ercilla, J., Ernst, A., Esposito, G., Ettori, F., Eufracino, Ezquerra Aguilera, W., Falcone, C., Falu, R. M., Feres, F., Ferlini, M., Fernandez, G., Fernandez-Rodriguez, D., Fileti, L., Fischetti, D., Florescu, N., Formigli, D., Fouladvand, F., Franco, N., Fresco, C., Frigoli, E., Furmaniuk, J., Gabaldo, K., Galli, M., Galli, S., Garbo, R., Garducci, S., Garg, S., Gavrielatos, G., Gensch, J., Giacchi, G., Giunio, L., Giustino, G., Goldberg, L., Goldsmit, R., Gommeaux, A., Gosselin, G., Govorov, A., Gonzalez Godinez, H., Gross, E., Grosz, C., Guagliumi, G., Hadad, W., Hadadi, L., Hansen, P. R., Harb, S., Hatrick, R., Hayrapetyan, H. G., Hernandez-Enriquez, M., Ho Heo, J., Horvath, I. G., Huan Loh, P., Ibrahim, A. M., Ierna, S., Ilic, I., Imperadore, F., Ionescu-Silva, E., Jacksch, R., James, S., Janiak, B., Jensen, S. E., Jeroen, S., Jugessur, R. K., Kala, P., Kambis, M., Kanakakis, J., Karamasis, G., Karchevsky, D., Karpovskiy, A., Kayaert, P., Kedev, S., Kemala, E., Ketteler, T., Khan, S. Q., Kharlamov, A., Kiernan, T., Kiviniem, T., Koltowski, L., Koskinas, K. C., Kouloumpinis, A., Kraaijeveld, A. O., Krizanic, F., Krotz, B., Kuczmik, W., Kukreja, N., Kuksa, D., Yav, K., Kyriakos, D., Labrunie, A., Laine, M., Lapin, O., Larosa, C., Latib, A., Lattuca, B., Lauer, B., Lefevre, T., Legrand, V., Lehto, P., Leiva-Pons, J. L., Leone, A. M., Lev, G., Lim, R., Limbruno, U., Linares Vicente, J. A., Lindsay, S., Linnartz, C., Liso, A., Lluberas, R., Locuratolo, N., Lokshyn, S., Lunde, K., Lupi, A., Magnavacchi, P., Maia, F., Mainar, V., Mancone, M., Manolios, M. G., Mansour, S., Mariano, E., Marques, K., Martins, H., Mckenzie, D., Meco, S., Meemook, K., Mehmed, K., Melikyan, A., Mellwig, K. P., Mendiz, O. A., Merkulov, E., Mesquita, H. G., Mezzapelle, G., Miloradovic, V., Mohamed, S., Mohammed, B., Mohammed, F., Mohammed, K., Mohanad, A., Morawiec, B., More, R., Moreno-Martinez, F. L., Mrevlje, B., Muhammad, F., Naveri, H., Nazzaro, M. S., Neary, P., Negus, B. H., Nelson Durval, F. G., Nick, H., Nilva, E., Oldroyd, K. G., Olivares Asencio, C., Omerovic, E., Ortiz, M. A., Ota, H., Otasevic, P., Otieno, H. A., Paizis, I., Papp, E., Pasquetto, G., Patsourakos, N. G., Peels, J., Pelliccia, F., Pennacchi, M., Penzo, C., Perez, P., Perkan, A., Petrou, E., Phipathananunth, W., Pierri, A., Pinheiro, L. F., Pipa, J. L., Piva, T., Polad, J., Porto, I., Poveda, J., Predescu, L., Prog, R., Puri, R., Raco, D. L., Ramazan, O., Ramazzotti, V., Rao, S. V., Raungaard, B., Reczuch, K., Rekik, S., Rhouati, A., Rigattieri, S., Rodriguez-Olivares, R., Roik, M., Romagnoli, E., Roman, A. J., Routledge, H., Rubartelli, P., Rubboli, A., Ruiz-Garcia, J., Russo, F., Ruzsa, Z., Ryding, A., Saad, A., Sabate, M., Sabouret, P., Sadowski, M., Saia, F., Sanchez Perez, I., Santoro, G. M., Sarenac, D., Saririan, M., Sarma, J., Schuetz, T., Sciahbasi, A., Sebastian, M., Sebik, R., Sesana, M., Hur, S. -H., Sganzerla, P., Shalva, R., Sharma, S., Sheiban, I., Shein, K. K., Shiekh, I. A., Sinha, M., Slhessarenko, J., Smith, D., Smyth, D. W., Sonmez, K., Sood, N., Sourgounis, A., Srdanovic, I., Stables, R. H., Stefanini, G. G., Stewart, J., Stoyanov, N., Suliman, A. A., Suryadevara, R., Suwannasom, P., Tange Veien, K., Tauchert, S., Tebet, M., Testa, L., Thury, A., Tilsted, H. H., Tiroch, K., Torres, A., Tosi, P., Traboulsi, M., Trani, C., Tresoldi, S., Tsigkas, G., Tueller, D., Turri, M., Udovichenko, A. E., Uretsky, B., Van Der Harst, P., Van Houwelingen, K. G., Vandoni, P., Vandormael, M., Varbella, F., Venkitachalam, C. G., Vercellino, M., Vidal-Perez, R., Vigna, C., Vignali, L., Vogt, F., Voudris, V., Vranckx, P., Vrolix, M., Vydt, T., Webster, M., Wijns, W., Woody, W., Wykrzykowska, J., Yazdani, S., Yildiz, A., Yurlevich, D., Zauith, R., Zekanovic, D., Zhao, M., Zimarino, M., Zingarelli, A., Abdelsamad, A. Y., Abo Shaera, E. S., Afshar, M. S., Agatiello, C., Aguiar, P., Ahmad, A. M., Akin, I., Alameda, M., Alegria-Barrero, E., Alejos, R., Alkhashab, K., Alkutshan, R. S. A., Almorraweh, A., Altnji, I., Alvarez Iorio, C., Anchidin, O., Angel, J., Antonopoulos, A., Apshilava, G., Arana, C., Ashikaga, T., Assomull, R., Atef, S. Z., Azmus, A. D., Azzalini, L., Azzouz, A., Baglioni, P., Bampas, G., Basil, M. P., Besh, D., Bhushan Sharm, A., Bien Hsien, H., Bihui, L., Bing-Chen, L., Biryukov, S., Blatt, A., Bocchi, E., Boghdady, A., Bonarjee, V. V. S., Bosnjak, I., Bravo Baptista, S., Brinckman, S. L., Buchter, B., Burzotta, F., Cacucci, M., Cagliyan, C. E., Cernetti, C., Chavez Mizraym, R., Choo, W. S., Choudhury, R., Cicco, N., Cisneros Clavijo, P., Citaku, H., Collet, J. P., Consuegra-Sanchez, L., Conte, M., Corral, J. M., Damonte, A., Dangoisse, V., Dastani, M., Della Rosa, F., Deora, S., Devadathan, S., Dharma, S., Di Giorgio, A., Diez, J. L., Dinesha, B., Duplancic, D., El Behwashi, M. F., Elghawaby, H., Elshahawy, O., Eskola, M. J., Etman, A., Eun Gyu, L., Fabiano, L., Facta, A., Fan, Y., Fang-Yang, H., Farag, E., Fathi, Y., Fazeli, N., Federico, P., Fereidoun, M. Z., Fernandez-Nofrerias, E., Flensted Lassen, J., Flessas, D., Fouad, H., Franco-Pelaez, J. A., Fu, Q., Furtado, R., Gadepalli, R., Gallino, R., Gasparetto, V., Gentiletti, A., Gholoobi, A., Ghosh, A. K., Gkizas, S., Golchha, S. K., Goncharov, A., Gossl, M., Gotberg, M., Greco, F., Grundeken, M. J., Gupta, D., Gupta, S., Guray, U., Hahalis, G., Hakim Vista, J., Hamid, M. A., Hammoudeh, A., Hasan, A. R. I., Hatsumura, F. E., Heintzen, M. P., Helal, T., Hetherington, S., Hewarathna, U. I., Hioki, H., Hissein, F., Ho-Ping, Y., Homs, S., Huber, K., Ibarra, F. M., Ielasi, A., Ipek, E., Jambunathan, R., Jamshidi, P., Jarrad, I., Javier, W., Jensen, J., Jimenez-Quevedo, P., Kalpak, O., Kan, J., Kanaan, T., Kao, D. H. M., Karamfiloff, K., Karegren, A., Karjalainen, P. P., Kasabov, R., Katsimagklis, G. D., Kaul, U., Khan, A., Kiemeneij, E., Kiviniemi, T., Kleiban, A., Komiyama, N., Konteva, M., Koshy, G., Krepsky, A. M., Kuljit, S., Kulkarni, P., Kumar, V., Kuznetsov, I., Lai, G., Lateef, M. A., Lawand, S., Le Hong, T., Lettieri, C., Levy, G., Lindvall, P., Maitra, A., Makowski, M., Mamas, M. A., Mandal, S. C., Mangalanandan, P., Marin, R., Mashhadi, M., Matsukage, T., Meier, B., Milosavljevic, B., Miro, S. S., Mitov, A., Moeriel, M., Moguel, R., Mohanty, A., Montalescot, G., Morsdorf, W., Moscato, F., Muniz, A., Muraglia, S., Myc, J., Nada, A., Nair, P., Namazi, M. H., Naraghipour, F., Nguyen, Q. N., Nicosia, A., Nikas, D., Ober, M., Ocaranza-Sanchez, R., Olivecrona, G., Pahlajani, D., Pandey, B. P., Parma, A., Parma, R., Patsilinakos, S. P., Pattam, J., Peddi, S., Perez, P. R., Peruga, J. Z., Pescoller, F., Petrov, I., Piatti, L., Pico-Aracil, F., Pina, J., Piroth, Z., Popa, V., Pourbehi, M. R., Pradhan, A. K., Prida, X. E., Purohit, B. V., Pyun, W. B., Quang Hung, D., Rada, I., Rafizadeh, O., Rahman, M. A., Rai, L., Ramsewak, A., Ravindran, R., Rodriguez De Leiras, O. S., Rodriguez Esteban, M., Roque Figueira, H., Saket, A., Sakhov, O., Saktheeswaran, M. K., Salachas, A., Sallam, A., Sampaolesi, A., Samy, A., Sanchis, J., Santaera, O., Santarelli, A., Santharaj, W. S., Sarango, B., Satheesh, S., Schmitz, T., Schuhlen, H., Seewoosagur, R., Segev, A., Seisembekov, V., Semitko, S., Sengottuvelu, G., Sepulveda Varela, P., Sethi, A., Sharma, A., Sharma, R. K., Shi, Hy., Simsek, M. A., Siqueira, B., Skalidis, E., Slawin, J., Sorokhtey, L., Spaulding, C., Srinivas, B., Srinivasan, M., Stakos, D., Stojkovic, S., Tacoy, G., Tawade, M., Tiecco, F., Tondi, S., Torresani, E. M., Tousek, P., Tran, T., Trantalis, G., Triantafyllou, K., Trivedi, R., Trivisonno, A., Tsui, K. L., Turkoglu, C., Tzung-Dau, W., Ueno, H., Urban, U., Uretsky, B. F., Uscumlic, A., Venugopal, V., Verney, R., Vilar, J. V., Villacorta, V. G., Vishwanath, R., Vlachojannis, G. J., Vlachojannis, M., Vlad, V., Von Birgelen, C., Vukcevic, V., Wahab, A., Waksman, R., Wei-Wen, L., Weisz, G., Whittaker, A., Yadav, A., Yokoi, Y., Zacharoulis, A., Zahran, M., Zamani, J., Ziakas, A., Zimmermann, J. P., and Cardiology
- Subjects
Hirudin ,Percutaneous ,Antithrombin ,medicine.medical_treatment ,Psychological intervention ,030204 cardiovascular system & hematology ,medical ,0302 clinical medicine ,Peptide Fragment ,Surveys and Questionnaires ,Surveys and Questionnaire ,Medicine ,Bivalirudin ,030212 general & internal medicine ,Societies, Medical ,Transradial ,Anticoagulant ,Hirudins ,Middle Aged ,Recombinant Protein ,Recombinant Proteins ,Femoral Artery ,Radial Artery ,Cardiology ,acute coronary syndrome ,bivalirudin ,transradial ,adult ,antithrombins ,cardiology ,femoral artery ,hirudins ,humans ,middle aged ,peptide fragments ,percutaneous coronary intervention ,recombinant proteins ,societies, medical ,surveys and questionnaires ,attitude of health personnel ,radial artery ,Acute coronary syndrome ,Cardiology and Cardiovascular Medicine ,Human ,medicine.drug ,Adult ,medicine.medical_specialty ,Attitude of Health Personnel ,medicine.drug_class ,MEDLINE ,Antithrombins ,03 medical and health sciences ,societies ,Percutaneous Coronary Intervention ,Internal medicine ,Humans ,Acute Coronary Syndrome ,Peptide Fragments ,Management of acute coronary syndrome ,business.industry ,Percutaneous coronary intervention ,medicine.disease ,business - Abstract
AIMS Our aim was to report on a survey initiated by the European Association of Percutaneous Cardiovascular Interventions (EAPCI) collecting the opinion of the cardiology community on the invasive management of acute coronary syndrome (ACS), before and after the MATRIX trial presentation at the American College of Cardiology (ACC) 2015 Scientific Sessions. METHODS AND RESULTS A web-based survey was distributed to all individuals registered on the EuroIntervention mailing list (n=15,200). A total of 572 and 763 physicians responded to the pre- and post-ACC survey, respectively. The radial approach emerged as the preferable access site for ACS patients undergoing invasive management with roughly every other responder interpreting the evidence for mortality benefit as definitive and calling for a guidelines upgrade to class I. The most frequently preferred anticoagulant in ACS patients remains unfractionated heparin (UFH), due to higher costs and greater perceived thrombotic risks associated with bivalirudin. However, more than a quarter of participants declared the use of bivalirudin would increase after MATRIX. CONCLUSIONS The MATRIX trial reinforced the evidence for a causal association between bleeding and mortality and triggered consensus on the superiority of the radial versus femoral approach. The belief that bivalirudin mitigates bleeding risk is common, but UFH still remains the preferred anticoagulant based on lower costs and thrombotic risks.
- Published
- 2016
16. Clinical Benefit of IVUS Guidance for Coronary Stenting: The ULTIMATE Step Toward Definitive Evidence?
- Author
-
di Mario, C., Koskinas, K. C., and Raber, L.
- Subjects
drug-eluting stents ,intravascular ultrasound ,restenosis ,stent thrombosis ,Coronary Angiography ,Stents ,Ultrasonography, Interventional ,Drug-Eluting Stents - Published
- 2018
17. P1222Intensification of lipid lowering therapy before and after publication of the IMPROVE-IT trial: A temporal analysis from the SPUM-ACS cohort
- Author
-
Gencer, B, primary, Carballo, D, additional, Nanchen, D, additional, Koskinas, K, additional, Klingenberg, R, additional, Raeber, L, additional, Auer, R, additional, Carballo, S, additional, Heg, D, additional, Windecker, S, additional, Luscher, T F, additional, Matter, C M, additional, Rodondi, N, additional, and Mach, F, additional
- Published
- 2019
- Full Text
- View/download PDF
18. P5500Acute coronary syndrome in young patients: frequency, mechanisms and clinical outcomes following percutaneous coronary intervention
- Author
-
Zanchin, C, primary, Ledwoch, S, additional, Ueki, Y, additional, Otsuka, T, additional, Karagiannis, A, additional, Losdat, S, additional, Stortecky, S, additional, Koskinas, K C, additional, Siontis, G C M, additional, Praz, F, additional, Billinger, M, additional, Valgimigli, M, additional, Pilgrim, T, additional, Windecker, S, additional, and Raeber, L, additional
- Published
- 2019
- Full Text
- View/download PDF
19. 127Validation of high-risk features for stent-related ischaemic events as proposed by the 2017 DAPT guidelines
- Author
-
Ueki, Y, primary, Zanchin, T, additional, Karagiannis, A, additional, Zanchin, C, additional, Stortecky, S, additional, Koskinas, K C, additional, Siontis, G C, additional, Praz, F, additional, Hunziker, L, additional, Heg, D, additional, Billinger, M, additional, Valgimigli, M, additional, Pilgrim, T, additional, Windecker, S, additional, and Raber, L, additional
- Published
- 2018
- Full Text
- View/download PDF
20. P766The effect of endothelial shear stress on fibroatheroma progression: a serial intravascular ultrasound, optical coherence tomography and blood flow simulation study
- Author
-
Zanchin, T Z, primary, Karagiannis, A, additional, Sakellaris, A, additional, Koskinas, K C, additional, Yamaji, K C, additional, Yasushi, U, additional, Fotiadis, D, additional, Roffi, M, additional, Pedrazzini, G, additional, Baumbach, A, additional, Michalis, L K, additional, Matter, C V, additional, Luescher, T F, additional, Windecker, S, additional, and Raeber, L, additional
- Published
- 2018
- Full Text
- View/download PDF
21. P3651In-vivo correlation of near-infrared spectroscopy lipid content and optical coherence tomography minimal cap thickness
- Author
-
Zanchin, C, primary, Ueki, Y, additional, Haener, J, additional, Zanchin, T, additional, Hunziker, L, additional, Stortecky, S, additional, Spirk, D, additional, Koskinas, K C, additional, Karagiannis, A, additional, Windecker, S, additional, and Raeber, L, additional
- Published
- 2018
- Full Text
- View/download PDF
22. 4179Cardiovascular outcomes following percutaneous coronary intervention among patients with cancer: observations from a large unselected cohort
- Author
-
Ueki, Y, primary, Voegeli, B, additional, Karagiannis, A, additional, Zanchin, T, additional, Zanchin, C, additional, Stortecky, S, additional, Koskinas, K C, additional, Moro, C, additional, Moschovitis, A, additional, Hunziker, L, additional, Valgimigli, M, additional, Pilgrim, T, additional, Suter, T, additional, Windecker, S, additional, and Raber, L, additional
- Published
- 2018
- Full Text
- View/download PDF
23. P4891Procedural safety and long-term clinical outcome of left atrial appendage closure according to predefined stroke risk
- Author
-
Haener, J.D., primary, Fuerholz, M., additional, Cherni, T., additional, Koskinas, K., additional, Piccolo, R., additional, Streit, S., additional, Praz, F., additional, Shakir, S., additional, Attinger-Toller, A., additional, Nietlispach, F., additional, Valgimigli, M., additional, Meier, B., additional, Windecker, S., additional, and Gloekler, S., additional
- Published
- 2017
- Full Text
- View/download PDF
24. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management:baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry
- Author
-
Lip, G. Y. H., Laroche, C., Dan, G. -A., Santini, M., Kalarus, Z., Rasmussen, L. H., Oliveira, M. M., Mairesse, G., Crijns, H. J. G. M., Simantirakis, E., Atar, D., Kirchhof, P., Vardas, P., Tavazzi, L., Maggioni, A. P., Raepers, M., El Husseini, Z., Dilling-Boer, D., Schurmans, J., Vijgen, J., Koopman, P., Huybrechts, W., Dormal, F., Blommaert, D., Deceuninck, O., Xhaet, O., Fragtrup Hellum, C., Mortensen, B., Ginnerup Sorensen, B., Joensen, A. M., Karlsdottir, A., Pehrson, S., Hummelshoj, J., Svenningsen, A-M., Tanggaard, L., Wiggers, P., Nygaard, A., Jonstrup, A., Petersen, J., Odgaard, A., Mortensen, M., Frost, L., Svenstrup Moller, D., Sondergaard, H. M., Christensen, P. D., Xydonas, S., Lioni, L., Dimopoulou, M., Georgiopoulos, G., Papatheodorou, E., Boutas, P., Kartalis, A., Nakou, H., Kanoupakis, E., Tahmatzidis, D., Styliadis, I., Vassilikos, V., Koskinas, K., Fragakis, N., Polymeropoulos, K., Maligos, G., Martignani, C., Diemberger, I., Boriani, G., Frisoni, J., Biffi, M., Ziacchi, M., Cimaglia, P., Fantecchi, E., Boni, S., Gabbai, D., Marchionni, N., Fumagalli, S., Bobbo, M., Ramani, F., Sinagra, G., Vitali-Serdoz, L., Nordio, A., Porto, A., Zecchin, M., Di Nora, C., Novo, S., Guarneri, F. P., Macaione, F., Rod, R., Stodle, R. M. O., Pervez, M. O., Smith, P., Buvarp, M., Ronnevik, P. K., Vold, A., Fuglestved, J., Stenshjemmet, E., Risberg, K., Sokal, A., Kubicius, A., Prochniewicz, E., Pokrywa, K., Rzeuski, R., Weryszko, A., Haberka, M., Gasior, Z., Slowikowski, A., Janion, M., Kolodziej, M., Janion-Sadowska, A., Drozdz, J., Stasiak, M., Jakubowski, P., Ciurus, T., Pawlak, M., Nowakowska, M., Wiklo, K., Kurpesa, M., Olejnik, A., Miarka, J., Streb, W., Zielinski, L., Dluzniewski, M., Tomaszewska-Kiecana, M., Opolski, G., Budnik, M., Kiliszek, M., Gorska, J., Mamcarz, A., Sliz, D., Makowiecki, K., Fuglewicz, A., Drozd, M., Garncarek, M., Musialik-Lydka, A., Markowicz-Pawlus, E., Kazmierczak, G., Leopold-Jadczyk, A., Koziel, M., Sobral, S., Pereira, H., Brandao Alves, L., Ribeiro, L., Miranda, R., Almeida, S., Madeira, F., Faustino, M., Oliveira, R., Gil, V., Braga, C., Martins, J., Rocha, S., Magalhaes, S., Ramos, V., Bernardo, R., Costa, F., Morgado, F., Galvao Santos, P., Almeida, N., Adragao, P., Carmo, P., Mariano Pego, G., Ferreira, J., Elvas, L., Ventura, M., Antonio, N., Ferreira, R., Damasio, A. F., Santos, A. R., Picarra, B., Neves, D., De Jesus, I., Amado, J., Sousa, P., Candeias, R., Lourenco, A., Pereira, A., Canario-Almeida, F., Fernandes, M., Ferreira, F., Machado, I., Quelhas, I., Guardado, J., Pereira, V., Cavaco, D., Lousinha, A., Valente, B., Silva, N., Cunha, P., Pimenta, R., Santos, S., Martins Oliveira, M., Vicente, S., Bernardes, A., Nunes Diogo, A., Rodrigues, E., Frazao Rodrigues De Sousa, J. M., Carpinteiro, L., Satendra, M., Cortez Dias, N., Neto, S., Gama Ribeiro, V., Goncalves, H., Primo, J., Adao, L., Oliveira, M., Costa, A., Delgado, A., Marmelo, B., Moreira, D., Santos, J., Santos, L., Rodrigues, B., Pop Moldovan, A., Darabantiu, D., Todea, B., Pop, C., Dicu, D., Filip, D., Mercea, D., Kozma, G., Schiopu, M., Catanescu, G., Popescu, C., Bobescu, E., Gabor, A., Buzea, A., Dan, A., Buzea Daha, I., Asan, N., Popescu, R., Bartos, D., Badila, E., Tintea, E., Grigore, C., Daraban, A. M., Sandulescu, A., Carp, A., Gherasim, D., Stoian, I. M., Baluta, M. M., Vintila, M. M., Popescu, M. I., Tica, O., Petrescu, L., Alina-Ramona, N., Dan, R., Cozma, D. C., Tutuianu, C., Mangea, M., Goanta, E., Van Opstal, J. M., Van Rennes, R., Mulder, B. A., Said, S. A. M., Folkeringa, R. J., Philippens, S., Blaauw, Y., Aksoy, I., Pluymen, M., Driessen, R., Limantoro, I., Lankveld, T., Mafi Rad, M., Hendriks, J., Van Unen, W. H., Meeder, J., Cardiologie, MUMC+: MA Cardiologie (9), and RS: CARIM - R2 - Cardiac function and failure
- Subjects
Male ,medicine.medical_specialty ,Registry ,Digoxin ,medicine.medical_treatment ,Physician's Practice Patterns ,Administration, Oral ,Pilot Projects ,Comorbidity ,Antiarrhythmic agent ,Amiodarone ,Anticoagulation ,Fibrinolytic Agents ,Atrial fibrillation ,Risk scores ,Risk Factors ,Physiology (medical) ,Internal medicine ,Antithrombotic ,Atrial Fibrillation ,medicine ,Prevalence ,Humans ,Registries ,Practice Patterns, Physicians' ,business.industry ,Anticoagulants ,Thrombosis ,medicine.disease ,Causality ,Europe ,Treatment Outcome ,Health Care Surveys ,Cardiology ,Female ,Cardiology and Cardiovascular Medicine ,business ,Anti-Arrhythmia Agents ,Fibrinolytic agent ,medicine.drug - Abstract
AIMS: Given the advances in atrial fibrillation (AF) management and the availability of new European Society of Cardiology (ESC) guidelines, there is a need for the systematic collection of contemporary data regarding the management and treatment of AF in ESC member countries.METHODS AND RESULTS: We conducted a registry of consecutive in- and outpatients with AF presenting to cardiologists in nine participating ESC countries. All patients with an ECG-documented diagnosis of AF confirmed in the year prior to enrolment were eligible. We enroled a total of 3119 patients from February 2012 to March 2013, with full data on clinical subtype available for 3049 patients (40.4% female; mean age 68.8 years). Common comorbidities were hypertension, coronary disease, and heart failure. Lone AF was present in only 3.9% (122 patients). Asymptomatic AF was common, particularly among those with permanent AF. Amiodarone was the most common antiarrhythmic agent used (∼20%), while beta-blockers and digoxin were the most used rate control drugs. Oral anticoagulants (OACs) were used in 80% overall, most often vitamin K antagonists (71.6%), with novel OACs being used in 8.4%. Other antithrombotics (mostly antiplatelet therapy, especially aspirin) were still used in one-third of the patients, and no antithrombotic treatment in only 4.8%. Oral anticoagulants were used in 56.4% of CHA2DS2-VASc = 0, with 26.3% having no antithrombotic therapy. A high HAS-BLED score was not used to exclude OAC use, but there was a trend towards more aspirin use in the presence of a high HAS-BLED score.CONCLUSION: The EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot Registry has provided systematic collection of contemporary data regarding the management and treatment of AF by cardiologists in ESC member countries. Oral anticoagulant use has increased, but novel OAC use was still low. Compliance with the treatment guidelines for patients with the lowest and higher stroke risk scores remains suboptimal.
- Published
- 2014
25. Current treatment of dyslipidaemia: PCSK9 inhibitors and statin intolerance
- Author
-
Koskinas, K, primary, Wilhelm, M, additional, and Windecker, S, additional
- Published
- 2016
- Full Text
- View/download PDF
26. Ranolazine enhances the efficacy of amiodarone for conversion of recent-onset atrial fibrillation
- Author
-
Koskinas, K. C., primary, Fragakis, N., additional, Katritsis, D., additional, Skeberis, V., additional, and Vassilikos, V., additional
- Published
- 2014
- Full Text
- View/download PDF
27. Ranolazine plus amiodarone for conversion of paroxysmal atrial fibrillation
- Author
-
Fragakis, N., primary, Koskinas, K. C., additional, Katritsis, D., additional, Rossios, K., additional, Sebris, V., additional, and Vassilikos, V., additional
- Published
- 2013
- Full Text
- View/download PDF
28. Sinus nodal response to adenosine relates to the severity of sinus node dysfunction
- Author
-
Fragakis, N., primary, Antoniadis, A. P., additional, Korantzopoulos, P., additional, Kyriakou, P., additional, Koskinas, K. C., additional, and Geleris, P., additional
- Published
- 2011
- Full Text
- View/download PDF
29. Abstract: P285 IDENTIFICATION OF EXTREMELY HIGH-RISK PLAQUES ON THE BASIS OF LOW ENDOTHELIAL SHEAR STRESS: IMPLICATIONS FOR RISK STRATIFICATION
- Author
-
Koskinas, K, primary, Coskun, A, additional, Chatzizisis, Y, additional, Jonas, M, additional, Feldman, C, additional, and Stone, P, additional
- Published
- 2009
- Full Text
- View/download PDF
30. Abstract: P286 HIGH-RISK CORONARY PLAQUES DEVELOP IN REGIONS OF PERSISTENTLY LOW ENDOTHELIAL SHEAR STRESS: A LONGTERM, SERIAL NATURAL HISTORY IVUS STUDY
- Author
-
Koskinas, K, primary, Chatzizisis, Y, additional, Coskun, A, additional, Jonas, M, additional, Stone, P, additional, and Feldman, C, additional
- Published
- 2009
- Full Text
- View/download PDF
31. Abstract: S2-15 DIFFERENTIAL ATHEROGENIC EFFECT OF LOW ENDOTHELIAL SHEAR STRESS IN PLAQUE-FREE VS. ATHEROSCLEROTIC CORONARY SEGMENTS: A SERIAL IVUS STUDY
- Author
-
Koskinas, K, primary, Chatzizisis, Y, additional, Jonas, M, additional, Coskun, A, additional, Groothuis, A, additional, Feldman, C, additional, and Stone, P, additional
- Published
- 2009
- Full Text
- View/download PDF
32. Abstract: P1115 DIFFERENTIAL ATHEROSCLEROTIC VASCULAR RESPONSE TO LOCAL ENDOTHELIAL SHEAR STRESS BASED ON THE SEVERITY OF HYPERLIPIDEMIA
- Author
-
Chatzizisis, Y, primary, Koskinas, K, additional, Jonas, M, additional, Coskun, A, additional, Edelman, E, additional, Stone, P, additional, and Feldman, C, additional
- Published
- 2009
- Full Text
- View/download PDF
33. Thin-Capped Atheromata With Reduced Collagen Content in Pigs Develop in Coronary Arterial Regions Exposed to Persistently Low Endothelial Shear Stress
- Author
-
Koskinas, K. C., Sukhova, Galina K., Baker, A. B., Papafaklis, M. I., Chatzizisis, Y. S., Coskun, A. U., Quillard, T., Jonas, M., Maynard, C., Antoniadis, Antonios, Shi, Guo-Ping, Libby, Peter, Edelman, Elazer Reuven, Feldman, Charles Lawrence, and Stone, Peter Howard
- Subjects
atherosclerosis ,collagen ,endothelial shear stress ,metalloproteinases ,natural history - Abstract
Objective—The mechanisms promoting the focal formation of rupture-prone coronary plaques in vivo remain incompletely understood. This study tested the hypothesis that coronary regions exposed to low endothelial shear stress (ESS) favor subsequent development of collagen-poor, thin-capped plaques. Approach and Results—Coronary angiography and 3-vessel intravascular ultrasound were serially performed at 5 consecutive time points in vivo in 5 diabetic, hypercholesterolemic pigs. ESS was calculated along the course of each artery with computational fluid dynamics at all 5 time points. At follow-up, 184 arterial segments with previously identified in vivo ESS underwent histopathologic analysis. Compared with other plaque types, eccentric thin-capped atheromata developed more in segments that experienced lower ESS during their evolution. Compared with lesions with higher preceding ESS, segments persistently exposed to low ESS (<1.2 Pa) exhibited reduced intimal smooth muscle cell content; marked intimal smooth muscle cell phenotypic modulation; attenuated procollagen-I gene expression; increased gene and protein expression of the interstitial collagenases matrix-metalloproteinase-1, -8, -13, and -14; increased collagenolytic activity; reduced collagen content; and marked thinning of the fibrous cap. Conclusions—Eccentric thin-capped atheromata, lesions particularly prone to rupture, form more frequently in coronary regions exposed to low ESS throughout their evolution. By promoting an imbalance of attenuated synthesis and augmented collagen breakdown, low ESS favors the focal evolution of early lesions toward plaques with reduced collagen content and thin fibrous caps—2 critical determinants of coronary plaque vulnerability.
- Published
- 2013
- Full Text
- View/download PDF
34. Selective Inhibition of Matrix Metalloproteinase-13 Increases Collagen Content of Established Mouse Atherosclerosis
- Author
-
Quillard, T., Tesmenitsky, Y., Croce, Kevin James, Travers, R., Shvartz, E., Koskinas, K. C., Sukhova, Galina K., Aikawa, Elena, Aikawa, Masanori, and Libby, Peter
- Subjects
atherosclerosis ,collagen ,inhibitor ,MMP-13 ,molecular imaging - Abstract
Objective—Evidence has linked collagen loss with the onset of acute coronary events. This study tested the hypothesis that selective matrix metalloproteinase-13 (MMP-13) collagenase inhibition increases collagen content in already established and nascent mouse atheromas. Methods and Results—In vitro and in situ experiments documented the selectivity and efficacy of an orally available MMP-13 inhibitor (MMP13i-A). In vivo observations monitored macrophage accumulation and MMP-13 activity using molecular imaging. After 10 weeks of MMP13i-A treatment, apolipoprotein E–deficient mice with evolving or established lesions exhibited reduced MMP-13 activity without affecting macrophage content, measured either by intravital microscopy or fluorescence reflectance imaging. Histological analysis indicated that MMP13-iA did not affect plaque size or macrophage or smooth muscle cell accumulation. Administration of MMP13i-A to mice with evolving or established atheromas substantially increased plaque interstitial collagen content in the intima and locally in the fibrous cap, compared with vehicle-treated controls. Analysis of collagen revealed thicker collagen fibers within the plaques of treated groups. Conclusion—Pharmacological MMP-13 inhibition yields collagen accumulation in plaques (a feature associated in humans with resistance to rupture), even in established plaques. This study, of considerable clinical relevance, furnishes new mechanistic insight into regulation of the plaque's extracellular matrix and validates molecular imaging for studying plaque biology.
- Published
- 2011
- Full Text
- View/download PDF
35. 2021 ESC/EACTS Guidelines for the management of valvular heart disease: Developed by the Task Force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS),Linee guida ESC/EACTS 2021 per il trattamento delle valvulopatie elaborate dalla Task Force per il trattamento delle valvulopatie della Società Europea di Cardiologia (ESC) e dell’Associazione Europea di Chirurgia Cardio-Toracica (EACTS)
- Author
-
Vahanian, A., Beyersdorf, F., Praz, F., Milojevic, M., Baldus, S., Bauersachs, J., Capodanno, D., Conradi, L., Bonis, M., Ruggero De Paulis, Delgado, V., Freemantle, N., Gilard, M., Haugaa, K. H., Jeppsson, A., Jüni, P., Pierard, L., Prendergast, B. D., Sádaba, J. R., Tribouilloy, C., Neumann, F. -J, Myers, P., Abdelhamid, M., Achenbach, S., Asteggiano, R., Barili, F., Borger, M. A., Carrel, T., Collet, J. -P, Foldager, D., Habib, G., Hassager, C., Irs, A., Iung, B., Jahangiri, M., Katus, H. A., Koskinas, K. C., Massberg, S., Mueller, C. E., Nielsen, J. C., Pibarot, P., Rakisheva, A., Roffi, M., Rubboli, A., Shlyakhto, E., Siepe, M., Sitges, M., Sondergaard, L., Sousa-Uva, M., Tarantini, G., and Zamorano, J. L.
36. Association between rs2200733 polymorphism on chromosome 4q25 and atrial fibrillation in a Greek population
- Author
-
Kalinderi, K., NIKOLAOS FRAGAKIS, Koskinas, K. C., Katritsis, D., Letsas, K., Efremidis, M., Korantzopoulos, P., Rossios, K., Pagourelias, E., Giannakopoulou, P., Mavroudi, M., Kyriakou, P., Skeberis, V., Geleris, P., Vassilikos, V., and Fidani, L.
37. Eligibility for marine omega-3 fatty acid supplementation after acute coronary syndromes.
- Author
-
Follonier C, Rabassa G, Branca M, Carballo D, Koskinas K, Heg D, Nanchen D, Räber L, Klingenberg R, Haller ML, Carballo S, Windecker S, Matter CM, Rodondi N, Mach F, and Gencer B
- Abstract
Background and Aims: The 2019 European Society of Cardiology guidelines for the management of dyslipidemia consider the use of high-dose marine omega-3 fatty acid (FA) eicosapentaenoic acid (EPA) supplementation (icosapent ethyl 2 × 2g/day) to lower residual cardiovascular risk in high-risk patients with hypertriglyceridemia. This study aimed to assess the eligibility for omega-3 FA-EPA supplementation in patients with acute coronary syndromes (ACS)., Methods: In a prospective Swiss cohort of patients hospitalized for ACS, eligibility for marine omega-3 FA-EPA, defined as plasma triglyceride levels ranging from 1.5 to 5.6 mmol/l, was assessed at baseline and one-year follow-up and compared across subgroups. Lipid-lowering therapy intensification with statin and ezetimibe was modelled to simulate a hypothetical systematic treatment and its effect on omega-3 FA-EPA supplementation eligibility., Results: Of 2643 patients, 98 % were prescribed statin therapy at discharge, including 62 % at a high-intensity regimen; 93 % maintained it after one year, including 53 % at a high-intensity regimen. The use of ezetimibe was 3 % at discharge and 7 % at one year. Eligibility was observed in 32 % (32 % men, 29 % women) one year post-ACS. After modelling systematic treatment with statins, ezetimibe, and both, eligibility decreased to 31 %, 25 % and 24 %, respectively. Eligibility was higher in individuals aged <70 (34 vs 25 %), smokers (38 vs 28 %), diabetics (46 vs 29 %), hypertensive (35 vs 29 %), and obese patients (46 vs 22 % for normal weight), all with p-values <0.001., Conclusion: In a contemporary Swiss cohort of patients with ACS, up to 32 % would be eligible for omega-3 FA-EPA supplementation one year after ACS, highlighting an opportunity to mitigate residual cardiovascular risk in patients with ACS and hypertriglyceridemia., (© 2024 The Authors.)
- Published
- 2024
- Full Text
- View/download PDF
38. Cardiovascular disease as part of Long COVID: A systematic review.
- Author
-
Tsampasian V, Bäck M, Bernardi M, Cavarretta E, Dębski M, Gati S, Hansen D, Kränkel N, Koskinas K, Niebauer J, Spadafora L, Frias Vargas M, Biondi-Zoccai G, and Vassiliou VS
- Abstract
Background: Long COVID syndrome has had a major impact on million patients' lives worldwide. The cardiovascular system is an important aspect of this multifaceted disease that may manifest in many ways. We have hereby performed a narrative review in order to identify the extent of the cardiovascular manifestations of the Long COVID syndrome., Methods and Results: An in-depth systematic search of the literature has been conducted for this narrative review. The systematic search of PubMed and Cochrane databases yielded 3,993, of which 629 underwent full text screening. A total of 78 studies were included in the final qualitative synthesis and data evaluation. The pathophysiology of the cardiovascular sequelae of Long COVID syndrome and the cardiac manifestations and complications of Long COVID syndrome are critically evaluated. In addition, potential cardiovascular risk factors are assessed, and preventive methods and treatment options are examined in this review., Conclusions: This systematic review poignantly summarises the evidence from the available literature regarding the cardiovascular manifestations of Long COVID syndrome and reviews potential mechanistic pathways, diagnostic approaches, preventive measures and treatment options., (© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.)
- Published
- 2024
- Full Text
- View/download PDF
39. [LDL-Lowering Drugs: What Are the Options In 2023?]
- Author
-
Corpataux N and Koskinas K
- Subjects
- Humans, Cholesterol, LDL, Hydroxymethylglutaryl-CoA Reductase Inhibitors adverse effects, Cardiovascular Diseases
- Abstract
Introduction: Cardiovascular diseases are the leading causes of death worldwide, claiming an estimated 17.9 million lives each year. There is a dose-dependent relationship between the absolute extent of exposure of the vascular system to low-density lipoprotein cholesterol (LDL) and the risk of atherosclerotic cardiovascular disease. Meta-analyses confirm the beneficial effects of LDL reduction. In addition to lifestyle modifications, which remain the cornerstone of primary and secondary prevention, it is pharmacologically possible to lower plasma LDL levels. This article highlights where we stand with lipid-lowering drugs, more than 30 years after the first statins were used therapeutically., Competing Interests: Noé Corpataux hat keine Interessenkonflikte. Konstantinos Koskinas bezieht Referentenhonorare/Honorare von Amgen, Sanofi, Daiichi Sankyo., (© 2023 Aerzteverlag medinfo AG.)
- Published
- 2023
40. EAPC Core Curriculum for Preventive Cardiology.
- Author
-
Wilhelm M, Abreu A, Adami PE, Ambrosetti M, Antonopoulou M, Biffi A, Cavarretta E, D'Ascenzi F, Gibson I, Grobbee DE, Iliou MC, Koskinas K, Marques-Vidal P, Nixdorff U, Papadakis M, Piepoli MF, Vassiliou V, Wood D, Dendale P, and Halle M
- Subjects
- Certification, Curriculum, Exercise, Humans, Cardiology, Cardiovascular Diseases diagnosis, Cardiovascular Diseases epidemiology, Cardiovascular Diseases prevention & control, Sports
- Abstract
Preventive cardiology encompasses the whole spectrum of cardiovascular disease (CVD) prevention, at individual and population level, through all stages of life. This includes promotion of cardiovascular (CV) health, management of individuals at risk of developing CVD, and management of patients with established CVD, through interdisciplinary care in different settings. Preventive cardiology addresses all aspects of CV health in the context of the social determinants of health, including physical activity, exercise, sports, nutrition, weight management, smoking cessation, psychosocial factors and behavioural change, environmental, genetic and biological risk factors, and CV protective medications. This is the first European Core Curriculum for Preventive Cardiology, which will help to standardize, structure, deliver, and evaluate training in preventive cardiology across Europe. It will be the basis for dedicated fellowship programmes and a European Society of Preventive Cardiology (EAPC) subspecialty certification for cardiologists, with the intention to improve quality and outcome in CVD prevention., (© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.)
- Published
- 2022
- Full Text
- View/download PDF
41. Electronic cigarettes and health with special focus on cardiovascular effects: position paper of the European Association of Preventive Cardiology (EAPC).
- Author
-
Kavousi M, Pisinger C, Barthelemy JC, De Smedt D, Koskinas K, Marques-Vidal P, Panagiotakos D, Prescott EB, Tiberi M, Vassiliou VS, and Løchen ML
- Subjects
- Adolescent, Humans, Electronic Nicotine Delivery Systems, Smoking Cessation, Cigarette Smoking, Cardiovascular Diseases diagnosis, Cardiovascular Diseases epidemiology, Cardiovascular Diseases prevention & control, Cardiology
- Abstract
Background: Tobacco use is the single largest preventable risk factor for premature death of non-communicable diseases and the second leading cause of cardiovascular disease. In response to the harmful effects of tobacco smoking, the use of electronic cigarettes (e-cigarettes) has emerged and gained significant popularity over the past 15 years. E-cigarettes are promoted as safe alternatives for traditional tobacco smoking and are often suggested as a way to reduce or quit smoking. However, evidence suggests they are not harmless., Discussion: The rapid evolution of the e-cigarette market has outpaced the legislator's regulatory capacity, leading to mixed regulations. The increasing use of e-cigarettes in adolescents and young individuals is of concern. While the long-term direct cardiovascular effects of e-cigarettes remain largely unknown, the existing evidence suggests that the e-cigarette should not be regarded as a cardiovascular safe product. The contribution of e-cigarette use to reducing conventional cigarette use and smoking cessation is complex, and the impact of e-cigarette use on long-term cessation lacks sufficient evidence., Conclusion: This position paper describes the evidence regarding the prevalence of e-cigarette smoking, uptake of e-cigarettes in the young, related legislations, cardiovascular effects of e-cigarettes and the impact of e-cigarettes on smoking cessation. Knowledge gaps in the field are also highlighted. The recommendations from the population science and public health section of the European Association of Preventive Cardiology are presented., (Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2021
- Full Text
- View/download PDF
42. [Diagnosis, Prevention and Treatment of Cardiovascular Disease in People with Diabetes and Prediabetes].
- Author
-
Koskinas K, Melmer A, Steiner N, Gübeli A, Wilhelm M, and Laimer M
- Subjects
- Humans, Risk Factors, Cardiovascular Diseases diagnosis, Cardiovascular Diseases prevention & control, Coronary Disease, Diabetes Mellitus, Type 2 complications, Diabetes Mellitus, Type 2 diagnosis, Heart Failure, Prediabetic State diagnosis, Prediabetic State drug therapy
- Abstract
Diagnosis, Prevention and Treatment of Cardiovascular Disease in People with Diabetes and Prediabetes Abstract. Diabetes is associated with an increased cardiovascular risk. In addition to optimizing glycemia, timely diagnosis and stringent control of cardiovascular risk factors is essential for individuals with diabetes. Therapeutic options include lifestyle-optimization, individualized drug therapy and targeted treatment of concomitant or secondary cardiovascular disease. Cardiovascular disease occurs more often in individuals with diabetes and includes heart failure, atrial fibrillation, coronary heart disease and sudden cardiac death. The correct choice of antidiabetic drugs and interventions can control cardiovascular risk factors, reduce cardiovascular risk and treat concomitant or secondary diseases in a targeted manner. This review is intended to provide guidance on diagnosis, treatment and choice of therapy for individuals with type 2 diabetes without and with concomitant or secondary cardiovascular disease.
- Published
- 2021
- Full Text
- View/download PDF
43. Clinical use of intracoronary imaging. Part 2: acute coronary syndromes, ambiguous coronary angiography findings, and guiding interventional decision-making: an expert consensus document of the European Association of Percutaneous Cardiovascular Interventions.
- Author
-
Johnson TW, Räber L, di Mario C, Bourantas C, Jia H, Mattesini A, Gonzalo N, de la Torre Hernandez JM, Prati F, Koskinas K, Joner M, Radu MD, Erlinge D, Regar E, Kunadian V, Maehara A, Byrne RA, Capodanno D, Akasaka T, Wijns W, Mintz GS, and Guagliumi G
- Subjects
- Acute Coronary Syndrome therapy, Adult, Aged, Case-Control Studies, Clinical Trials as Topic, Consensus, Coronary Angiography methods, Coronary Artery Disease pathology, Decision Making, European Union organization & administration, Female, Hemodynamics physiology, Humans, Male, Middle Aged, Percutaneous Coronary Intervention methods, Plaque, Atherosclerotic pathology, Predictive Value of Tests, Rupture diagnostic imaging, Spectroscopy, Near-Infrared methods, Stents, Tomography, Optical Coherence methods, Ultrasonography, Interventional methods, Acute Coronary Syndrome diagnostic imaging, Coronary Angiography trends, Coronary Artery Disease therapy, Percutaneous Coronary Intervention adverse effects
- Abstract
This consensus document is the second of two reports summarizing the views of an expert panel organized by the European Association of Percutaneous Cardiovascular Interventions (EAPCI) on the clinical use of intracoronary imaging including intravascular ultrasound (IVUS), optical coherence tomography (OCT), and near infrared spectroscopy (NIRS)-IVUS. Beyond guidance of stent selection and optimization of deployment, invasive imaging facilitates angiographic interpretation and may guide treatment in acute coronary syndrome. Intravascular imaging can provide additional important diagnostic information when confronted with angiographically ambiguous lesions and allows assessment of plaque morphology enabling identification of vulnerability characteristics. This second document focuses on useful imaging features to identify culprit and vulnerable coronary plaque, which offers the interventional cardiologist guidance on when to adopt an intracoronary imaging-guided approach to the treatment of coronary artery disease and provides an appraisal of intravascular imaging-derived metrics to define the haemodynamic significance of coronary lesions., (Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2019
- Full Text
- View/download PDF
44. Angiographic derived endothelial shear stress: a new predictor of atherosclerotic disease progression.
- Author
-
Bourantas CV, Ramasamy A, Karagiannis A, Sakellarios A, Zanchin T, Yamaji K, Ueki Y, Shen X, Fotiadis DI, Michalis LK, Mathur A, Serruys PW, Garcia-Garcia HM, Koskinas K, Torii R, Windecker S, and Räber L
- Subjects
- Aged, Cohort Studies, Coronary Angiography methods, Coronary Artery Disease physiopathology, Coronary Circulation physiology, Disease Progression, Endothelium, Vascular diagnostic imaging, Female, Humans, Male, Middle Aged, Multivariate Analysis, Predictive Value of Tests, ROC Curve, Retrospective Studies, Risk Assessment, Coronary Artery Disease diagnostic imaging, Endothelium, Vascular pathology, Imaging, Three-Dimensional, ST Elevation Myocardial Infarction diagnostic imaging, Ultrasonography, Interventional methods
- Abstract
Aims: To examine the efficacy of angiography derived endothelial shear stress (ESS) in predicting atherosclerotic disease progression., Methods and Results: Thirty-five patients admitted with ST-elevation myocardial infarction that had three-vessel intravascular ultrasound (IVUS) immediately after revascularization and at 13 months follow-up were included. Three dimensional (3D) reconstruction of the non-culprit vessels were performed using (i) quantitative coronary angiography (QCA) and (ii) methodology involving fusion of IVUS and biplane angiography. In both models, blood flow simulation was performed and the minimum predominant ESS was estimated in 3 mm segments. Baseline plaque characteristics and ESS were used to identify predictors of atherosclerotic disease progression defied as plaque area increase and lumen reduction at follow-up. Fifty-four vessels were included in the final analysis. A moderate correlation was noted between ESS estimated in the 3D QCA and the IVUS-derived models (r = 0.588, P < 0.001); 3D QCA accurately identified segments exposed to low (<1 Pa) ESS in the IVUS-based reconstructions (AUC: 0.793, P < 0.001). Low 3D QCA-derived ESS (<1.75 Pa) was associated with an increase in plaque area, burden, and necrotic core at follow-up. In multivariate analysis, low ESS estimated either in 3D QCA [odds ratio (OR): 2.07, 95% confidence interval (CI): 1.17-3.67; P = 0.012) or in IVUS (<1 Pa; OR: 2.23, 95% CI: 1.23-4.03; P = 0.008) models, and plaque burden were independent predictors of atherosclerotic disease progression; 3D QCA and IVUS-derived models had a similar accuracy in predicting disease progression (AUC: 0.826 vs. 0.827, P = 0.907)., Conclusions: 3D QCA-derived ESS can predict disease progression. Further research is required to examine its value in detecting vulnerable plaques., (Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2018. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2019
- Full Text
- View/download PDF
45. Effects of coronary artery disease in patients undergoing transcatheter aortic valve implantation: A study of age- and gender-matched cohorts.
- Author
-
Franzone A, Stortecky S, Räber L, Heg D, Yamaji K, Piccolo R, Asami M, Lanz J, Praz F, Koskinas K, Zanchin T, Wenaweser P, Valgimigli M, Jüni P, Pilgrim T, and Windecker S
- Subjects
- Age Factors, Aged, Aged, 80 and over, Cohort Studies, Coronary Artery Disease diagnostic imaging, Death, Female, Follow-Up Studies, Humans, Male, Prospective Studies, Registries, Risk Factors, Sex Factors, Transcatheter Aortic Valve Replacement adverse effects, Coronary Artery Disease mortality, Coronary Artery Disease surgery, Transcatheter Aortic Valve Replacement mortality, Transcatheter Aortic Valve Replacement trends
- Abstract
Background: The prognostic role of concomitant coronary artery disease (CAD) among patients undergoing transcatheter aortic valve implantation (TAVI) is still uncertain., Methods: Data from the Bern TAVI Registry and the Bern PCI Registry were analyzed. Patients with concomitant CAD undergoing TAVI (TAVI+CAD) were age- and gender-matched to the following two cohorts: patients without CAD undergoing TAVI (TAVI-noCAD) and patients with stable CAD undergoing percutaneous coronary intervention (CAD-noAS). Major adverse cardiovascular and cerebrovascular events (MACCE), defined as the composite of cardiovascular death, myocardial infarction, or cerebrovascular events, represented the primary endpoint at 1-year., Results: Out of 9478 procedures performed between 2007 and 2013 (807 TAVI; 8671 PCI), three cohorts, each including 248 subjects, were derived. At 1-year, MACCE were significantly increased among TAVI+CAD compared with TAVI-noCAD (16.8% vs. 9.8%, hazard ratio, HR, 1.75, 95% confidence intervals, CI, 1.06-2.89, p=0.030) and CAD-noAS patients (16.8% vs. 9.5%, HR 1.85, 95%CI 1.11-3.09, p=0.018) whereas no difference was found between TAVI-noCAD and CAD-noAS patients. The higher rate of MACCE among TAVI+CAD patients was mainly driven by an increased risk of cardiovascular mortality compared with the TAVI-noCAD (HR 1.86, 95%CI 1.03-3.36, p=0.040) and CAD-noAS cohorts (HR 2.29, 95%CI 1.22-4.30, p=0.010). The 1-year rate of MACCE was similar between TAVI-noCAD and CAD-noAS patients (9.8% vs. 9.5%, HR 1.05, 95%CI 0.59-1.87, p=0.86)., Conclusions: Concomitant CAD in the setting of TAVI conveyed an increased risk of ischemic events and cardiovascular mortality at 1-year follow-up., (Copyright © 2017 Elsevier B.V. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
46. Experimental investigation of the flow of a blood analogue fluid in a replica of a bifurcated small artery.
- Author
-
Anastasiou AD, Spyrogianni AS, Koskinas KC, Giannoglou GD, and Paras SV
- Subjects
- Humans, Stress, Mechanical, Arteries physiology, Biomimetic Materials, Blood Circulation, Pulsatile Flow
- Abstract
The scope of this work is to study the pulsatile flow of a blood mimicking fluid in a micro channel that simulates a bifurcated small artery, in which the Fahraeus-Lindqvist effect is insignificant. An aqueous glycerol solution with small amounts of xanthan gum was used for simulating viscoelastic properties of blood and in vivo flow conditions were reproduced. Local flow velocities were measured using micro Particle Image Velocimetry (μ-PIV). From the measured velocity distributions, the wall shear stress (WSS) and its variation during a pulse were estimated. The Reynolds numbers employed are relatively low, i.e. similar to those prevailing during blood flow in small arteries. Experiments both with a Newtonian and a non-Newtonian fluid (having asymptotic viscosity equal to the viscosity of the Newtonian one) proved that the common assumption that blood behaves as a Newtonian fluid is not valid for blood flow in small arteries. It was also shown that the outer wall of the bifurcation, which is exposed to a lower WSS, is more predisposed to atherosclerotic plaque formation. Moreover, this region in small vessels is shorter than the one in large arteries, as the developed secondary flow decays faster. Finally, the WSS values in small arteries were found to be lower than those in large ones., (Copyright © 2011 IPEM. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
47. Safety of dental extractions during uninterrupted single or dual antiplatelet treatment.
- Author
-
Lillis T, Ziakas A, Koskinas K, Tsirlis A, and Giannoglou G
- Subjects
- Aged, Aspirin administration & dosage, Aspirin adverse effects, Clopidogrel, Dose-Response Relationship, Drug, Drug Therapy, Combination, Female, Follow-Up Studies, Greece epidemiology, Hemostatics administration & dosage, Humans, Incidence, Male, Middle Aged, Platelet Aggregation Inhibitors administration & dosage, Platelet Aggregation Inhibitors adverse effects, Postoperative Hemorrhage chemically induced, Postoperative Hemorrhage prevention & control, Retrospective Studies, Ticlopidine administration & dosage, Ticlopidine adverse effects, Ticlopidine therapeutic use, Time Factors, Aspirin therapeutic use, Platelet Aggregation Inhibitors therapeutic use, Postoperative Hemorrhage epidemiology, Ticlopidine analogs & derivatives, Tooth Extraction methods
- Abstract
Optimal dental management in patients on long-term antiplatelet treatment is not clearly defined. Antiplatelet discontinuation increases the risk of thrombotic complications, whereas uninterrupted antiplatelet therapy, which is the currently recommended approach, is assumed to increase the bleeding hazard after dental procedures. We sought to prospectively compare the risk of immediate and late postextraction bleeding in patients receiving uninterrupted single or dual antiplatelet therapy. We recruited 643 consecutive patients referred for dental extractions. In total 111 (17.3%) were on clinically indicated antiplatelet therapy: aspirin (n = 42), clopidogrel (n = 36), and aspirin and clopidogrel (n = 33). Controls (n = 532, 82.7%) were not on antiplatelet treatment. Immediate and late bleeding complications were recorded. Compared to controls the risk of prolonged immediate bleeding was higher in patients on dual antiplatelet therapy (relative risk [RR] 177.3, 95% confidence interval [CI] 43.5 to 722, p <0.001) but not in patients on aspirin alone (RR = 6.3, 95% CI 0.6 to 68.4, p = 0.2) or clopidogrel alone (RR = 7.4, 95% CI 0.7 to 79.5, p = 0.18); however, all immediate bleeding complications in all treatment groups were successfully managed with local hemostatic measures. No patient developed any late hemorrhage. In conclusion, dental extractions may be safely performed in patients receiving single or dual antiplatelet therapy when appropriate local hemostatic measures are taken, thus averting thrombotic risk of temporary antiplatelet discontinuation., (Copyright © 2011 Elsevier Inc. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
48. Kinetics and prognostic value of inflammatory-sensitive protein, IL-6, and white blood cell levels in patients undergoing coronary stent implantation.
- Author
-
Ziakas A, Gavrilidis S, Giannoglou G, Souliou E, Koskinas K, Gemitzis K, Hatzimiltiadis S, Efthimiadis G, Paraskevaidis S, Hatzitolios A, Savopoulos C, and Parharidis G
- Subjects
- Aged, Angioplasty, Female, Humans, Kinetics, Male, Middle Aged, Prognosis, Prospective Studies, C-Reactive Protein metabolism, Coronary Disease surgery, Fibrinogen metabolism, Interleukin-6 blood, Leukocyte Count, Stents
- Abstract
Background: The levels of interleukin-6 (IL-6), white blood cells (WBCs), and some inflammatory-sensitive proteins (ISPs), such as fibrinogen (FIB) and C-reactive protein (CRP), have been related to coronary stent restenosis. The aim was to investigate the time course of the levels of IL-6, WBC, and several ISPs, i.e. FIB, CRP, cerruloplasmin (CER), haptoglobin (HPT), alpha-1 antitrypsin (A1AT), and alpha-1 acid glycoprotein (A1GP), after successful coronary stenting in patients with stable angina and to relate them to prognosis., Material/methods: FIB, CRP, IL-6, CER, HPT, A1AT, A1GP, and WBC levels were measured in 40 patients with stable angina before, and 6, 12, 24, 48, and 72 hours and 6 months after successful coronary stenting. The patients were followed up for 12 months., Results: FIB levels increased significantly (p<0.05) 48 hours, CRP and WBC count 24 hours, CER, HPT, A1AT, and A1GP 72 hours, and IL-6 6 hours after stenting. All the levels remained unchanged in 20 control patients undergoing coronary angiography. During follow-up, stent restenosis occurred in 7 patients. Time-course and mean values of all the studied substances did not significantly differ in patients with or without restenosis (p>0.05)., Conclusions: FIB, CRP, IL-6, CER, HPT, A1AT, A1GP, and WBC levels increase significantly after stenting, but they are not related to prognosis.
- Published
- 2009
49. Coronary calcification in patients with end-stage renal disease: a novel endocrine disorder?
- Author
-
Efstratiadis G, Koskinas K, and Pagourelias E
- Subjects
- Blood Proteins metabolism, Calcinosis classification, Calcinosis therapy, Calcium metabolism, Calcium-Binding Proteins metabolism, Coronary Artery Disease classification, Coronary Artery Disease therapy, Endocrine System Diseases classification, Extracellular Matrix Proteins metabolism, Humans, Kidney Failure, Chronic metabolism, Minerals antagonists & inhibitors, Minerals metabolism, Muscle, Smooth, Vascular metabolism, Myocytes, Smooth Muscle metabolism, Osteoprotegerin metabolism, Phosphorus metabolism, alpha-2-HS-Glycoprotein, Matrix Gla Protein, Calcinosis etiology, Coronary Artery Disease etiology, Kidney Failure, Chronic complications
- Abstract
Cardiovascular mortality is significantly increased among patients with end-stage renal disease. The commonly observed vascular calcification in such patients has been considered as one of the causative factors. In patients undergoing dialysis, the incidence of coronary artery calcification is 2-5 times higher compared to patients with normal renal function and angiographically demonstrated coronary artery disease. Moreover, epidemiological studies have revealed a significant correlation of the extent of coronary artery calcification with the severity of underlying atherosclerotic lesions. Vascular calcification was initially considered as a passive process of hydroxyapatite deposition due to elevated plasma concentrations of calcium and phosphate. Nevertheless, there is a growing body of evidence that vascular calcification is an actively regulated and cell-mediated process. This phenomenon includes phenotypic alterations of vascular smooth muscle cells mainly resulting from an imbalance between promoters (such as increased Ca x P product) and inhibitors (fetuin-A, GLA protein, osteoprotegerin) of mineral deposition. With regard to the therapeutic approach, despite the evident effectiveness of both traditional and innovative remedies in the management of metabolic and electrolytic abnormalities of patients with end-stage renal disease, an individualized intervention based on etiopathogenesis is really required.
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.